Alimera Sciences (ALIM) 8-K 18 Sep 15 Index to Financial Statements Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	ALIMERA SCIENCES INC
Entity Central Index Key	1,267,602
Document Type	8-K
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Entity Filer Category	Accelerated Filer

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 61,328	$ 76,697	$ 12,628
Accounts receivable, net	3,423	850	500
Prepaid expenses and other current assets	2,913	3,234	3,474
Inventory, net	2,052	1,734	1,786
Deferred financing costs	597	754	250
Total current assets	70,313	83,269	18,638
PROPERTY AND EQUIPMENT — at cost less accumulated depreciation	2,511	1,653	982
INTANGIBLE ASSET, net		24,490	0
TOTAL ASSETS	96,835	109,412	19,620
CURRENT LIABILITIES:
Accounts payable	4,729	5,021	1,735
Accrued expenses	1,709	954	934
Accrued milestone payments	0	2,000	0
Outsourced services payable	827	1,466	603
Note payable	4,472	1,023	1,667
Capital lease obligations	253	11	10
Total current liabilities	11,990	10,475	4,949
NON-CURRENT LIABILITIES:
Derivative warrant liability	13,592	16,098	16,381
Note payable, net of discount — less current portion	29,808	33,065	3,194
Other non-current liabilities	$ 873	$ 255	$ 21
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ (DEFICIT) EQUITY:
Common stock, $.01 par value — 100,000,000 shares authorized, 44,320,342 shares issued and outstanding at December 31, 2014 and 31,610,991 shares issued and outstanding at December 31, 2013	$ 444	$ 443	$ 316
Additional paid-in capital	294,054	292,851	240,135
Accumulated deficit	(323,048)	(313,255)	(277,345)
Accumulated other comprehensive loss	(1,170)	(812)	(488)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	40,572	49,519	(4,925)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 96,835	$ 109,412	$ 19,620
Preferred Stock
STOCKHOLDERS’ (DEFICIT) EQUITY:
Preferred stock
Series A convertible preferred stock
STOCKHOLDERS’ (DEFICIT) EQUITY:
Preferred stock	$ 19,227	$ 19,227	$ 32,045
Series B convertible Preferred Stock
STOCKHOLDERS’ (DEFICIT) EQUITY:
Preferred stock	49,568	49,568	0
Common Stock
STOCKHOLDERS’ (DEFICIT) EQUITY:
Common stock warrants	$ 1,497	$ 1,497	$ 412

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	44,386,290	44,320,342	31,610,991
Common stock, shares outstanding	44,386,290	44,320,342	31,610,991
Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Series A convertible preferred stock
Preferred stock, shares authorized	1,300,000	1,300,000	1,300,000
Preferred stock, shares issued	600,000	600,000	1,000,000
Preferred stock, shares outstanding	600,000	600,000	1,000,000
Preferred stock, liquidation preference	$ 24,000,000	$ 24,000,000	$ 40,000,000
Series B convertible Preferred Stock
Preferred stock, shares authorized	8,417	8,417	8,417
Preferred stock, shares issued	8,416.251	8,416.251	0
Preferred stock, shares outstanding	8,416.251	8,416.251	0
Preferred stock, liquidation preference	$ 50,750,000	$ 50,750,000	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
NET REVENUE	$ 3,938	$ 2,084	$ 8,423	$ 1,872
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(283)	(564)	(1,442)	(1,863)
GROSS PROFIT	3,655	1,520	6,981	9
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,329	2,754	11,811	8,858
GENERAL AND ADMINISTRATIVE EXPENSES	3,619	2,894	12,371	9,475
SALES AND MARKETING EXPENSES	7,129	3,283	15,087	15,942
DEPRECIATION AND AMORTIZATION	572	33	659	138
OPERATING EXPENSES	14,649	8,964	39,928	34,413
NET LOSS FROM OPERATIONS	(10,994)	(7,444)	(32,947)	(34,404)
INTEREST EXPENSE AND OTHER	(1,122)	(129)	(2,090)	(533)
UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET	(114)	(56)	(542)	825
LOSS ON EARLY EXTINGUISHMENT OF DEBT			(440)	(153)
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY	2,506	(13,130)	283	(11,964)
NET LOSS BEFORE TAXES	(9,724)	(20,759)	(35,736)	(46,229)
PROVISION FOR TAXES	$ (69)	$ 0	(174)	0
NET LOSS			(35,910)	(46,229)
BENEFICIAL CONVERSION FEATURE OF PREFERRED STOCK			(750)	(4,950)
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS			$ (36,660)	$ (51,179)
NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS — Basic and diluted (in dollars per share)	$ (0.22)	$ (0.58)	$ (0.91)	$ (1.62)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted (in shares)	44,347,639	35,853,869	40,397,224	31,579,553

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net loss	$ (9,793)	$ (20,759)	$ (35,910)	$ (46,229)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(358)	4	(324)	(488)
TOTAL OTHER COMPREHENSIVE LOSS	(358)	4	(324)	(488)
COMPREHENSIVE LOSS	$ (10,151)	$ (20,755)	$ (36,234)	$ (46,717)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($)	Total	Series B Convertible Preferred Stock	Common Stock Issued	Common Stock	Common StockCommon Stock Issued	Preferred StockSeries A Convertible Preferred Stock	Preferred StockSeries B Convertible Preferred Stock	Additional Paid-In Capital	Additional Paid-In CapitalCommon Stock Issued	Common Stock Warrants	Accumulated Deficit	Accumulated Other Comprehensive Loss
BALANCE at Dec. 31, 2012	$ 39,144,000			$ 315,000		$ 32,045,000	$ 0	$ 237,485,000		$ 415,000	$ (231,116,000)	$ 0
BALANCE (in shares) at Dec. 31, 2012				31,541,286		1,000,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs		$ 0	$ 53,000		$ 0				$ 53,000
Issuance of stock, net of issuance costs (in shares)					26,123
Exercise of stock options	$ 72,000			$ 1,000				71,000
Exercise of stock options (in shares)	43,582			43,582
Modification of common stock warrants	$ 46,000									46,000
Issuance of common stock warrants	0							49,000		(49,000)
Intrinsic value of beneficial conversion feature	0					$ (4,950,000)		4,950,000
Accretion of beneficial conversion feature	(4,950,000)					4,950,000		(4,950,000)
Stock-based compensation expense	2,477,000							2,477,000
Net loss	(46,229,000)										(46,229,000)
Foreign currency translation adjustments	(488,000)											(488,000)
BALANCE at Dec. 31, 2013	(4,925,000)			$ 316,000		$ 32,045,000	$ 0	240,135,000		412,000	(277,345,000)	(488,000)
BALANCE (in shares) at Dec. 31, 2013				31,610,991		1,000,000	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs		49,568,000	$ 35,209,000		$ 63,000		$ 49,568,000		$ 35,146,000
Issuance of stock, net of issuance costs (in shares)					6,284,915		8,416
Exercise of stock options	$ 774,000			$ 4,000				770,000
Exercise of stock options (in shares)	391,307			391,307
Conversion of preferred stock	$ 0			$ 60,000		$ (12,818,000)		12,758,000
Conversion of preferred stock (in shares)				6,015,037		(400,000)
Modification of common stock warrants	1,277,000									1,277,000
Issuance of common stock warrants	0			$ 18,092				192,000		(192,000)
Intrinsic value of beneficial conversion feature	0	$ (750,000)					$ (750,000)	750,000
Accretion of beneficial conversion feature	(750,000)						750,000	(750,000)
Stock-based compensation expense	3,850,000							3,850,000
Net loss	(35,910,000)										(35,910,000)
Foreign currency translation adjustments	(324,000)											(324,000)
BALANCE at Dec. 31, 2014	$ 49,519,000			$ 443,000		$ 19,227,000	$ 49,568,000	$ 292,851,000		$ 1,497,000	$ (313,255,000)	$ (812,000)
BALANCE (in shares) at Dec. 31, 2014				44,320,342		600,000	8,416
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	65,948
Net loss	$ (9,793,000)
BALANCE at Mar. 31, 2015	$ 40,572,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,793,000)	$ (20,759,000)	$ (35,910,000)	$ (46,229,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	558,000	36,000	659,000	138,000
Inventory reserve			0	410,000
Unrealized foreign currency transaction gain	114,000	56,000	542,000	(825,000)
Amortization of deferred financing costs and debt discount	175,000	42,000	466,000	159,000
Loss on early extinguishment of debt			440,000	153,000
Stock option expense	1,078,000	933,000	3,850,000	2,477,000
Change in fair value of derivative warrant liability	(2,506,000)	13,130,000	(283,000)	11,964,000
Changes in assets and liabilities:
Accounts receivable	(2,666,000)	(775,000)	(444,000)	(483,000)
Prepaid expenses and other current assets	171,000	1,054,000	206,000	(1,355,000)
Inventory	(455,000)	548,000	(135,000)	(1,416,000)
Accounts payable	272,000	111,000	2,987,000	(259,000)
Accrued expenses and other current liabilities	(1,708,000)	(592,000)	3,077,000	(2,347,000)
Other long-term liabilities	58,000	(2,000)	244,000	(208,000)
Net cash used in operating activities	(14,702,000)	(6,218,000)	(24,301,000)	(37,821,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment of license intangible (Note 6)			(25,000,000)	0
Purchases of property and equipment	(160,000)	(12,000)	(842,000)	(973,000)
Net cash used in investing activities	(160,000)	(12,000)	(25,842,000)	(973,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	125,000	287,000	774,000	72,000
Proceeds from sale of common stock	0	37,500,000	37,598,000	53,000
Payment of issuance cost of common stock	0	(2,389,000)	(2,389,000)	0
Proceeds from issuance of Series B convertible preferred stock			50,000,000	0
Payment of Series B convertible preferred stock offering costs	(327,000)	0	(105,000)	0
Proceeds from issuance of notes payable			35,000,000	5,000,000
Payment of debt issuance costs			(1,016,000)	(291,000)
Payment of principal on notes payable	0	(417,000)	(4,861,000)	(3,169,000)
Payment of debt extinguishment costs			(246,000)	0
Payments on capital lease obligations	(3,000)	(2,000)	(10,000)	(11,000)
Net cash provided by financing activities	(205,000)	34,979,000	114,745,000	1,654,000
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS	(302,000)	(51,000)	(533,000)	204,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(15,369,000)	28,698,000	64,069,000	(36,936,000)
CASH AND CASH EQUIVALENTS — Beginning of year	76,697,000	12,628,000	12,628,000	49,564,000
CASH AND CASH EQUIVALENTS — End of year	61,328,000	41,326,000	76,697,000	12,628,000
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	954,000	89,000	1,247,000	607,000
Income taxes paid			0	0
Payments of dividends			0	0
Supplemental schedule of noncash investing and financing activities:
Conversion of Series A Convertible Preferred Stock to common stock			12,818,000	0
Series B Convertible Preferred Stock offering costs accrued but unpaid			327,000	0
Property and equipment acquired under capital leases	$ 806,000	$ 0	$ 0	$ 33,000

Nature of Operations

Nature of Operations	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS Alimera Sciences, Inc., and its subsidiaries (the Company), is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware. The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company’s management believes these diseases are not well treated with current therapies and represent a significant underserved market opportunity. The Company’s only commercial product is ILUVIEN ® , which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, and the United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Union (EU) and European Economic Area countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in the EU, the Company has committed to conduct a five -year, post-authorization, open label registry study of ILUVIEN in 800 patients. The Company launched ILUVIEN in the United Kingdom and Germany in the second quarter of 2013 and in Portugal and the U.S. in the first quarter of 2015. The Company was able to launch in Germany without price restrictions, but continues to work with the statutory health insurance funds in Germany to streamline reimbursement for ILUVIEN. In October 2013, the United Kingdom’s National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination recommending ILUVIEN funding, taking into consideration a simple patient access scheme (PAS) for the treatment of pseudophakic eyes (eyes with an artificial lens) in chronic DME patients considered insufficiently responsive to available therapies. Further, in February 2014, the Scottish Medicines Consortium, after completing its assessment and review of a similar simple PAS, announced that it had accepted ILUVIEN for restricted use within the National Health Services Scotland. In July 2013, the Transparency Commission (Commission de la Transparence or CT) of the French National Health Authority (Haute Autorite de Sante) issued a favorable opinion for the reimbursement and hospital listing of ILUVIEN by the French National Health Insurance for the treatment of chronic DME considered insufficiently responsive to available therapies. The Company continues to negotiate with the French authorities, but has not yet reached an agreement on price. In July 2014, the Company reached agreement with INFARMED, the marketing authorization body of the Portuguese Ministry of Health, for the pricing and reimbursement of ILUVIEN for the public sector in Portugal.	NATURE OF OPERATIONS Alimera Sciences, Inc., and its wholly-owned subsidiaries, (the Company) is a pharmaceutical company that specializes in the research, development, and commercialization of ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware. The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company’s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company’s only commercial product is ILUVIEN ® , which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom and has been recommended for marketing authorization in Poland. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Union (EU) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in these countries, the Company has committed to conduct a five -year, post-authorization, open label registry study of ILUVIEN in 800 patients treated per the labeled indication. The Company launched ILUVIEN in the United Kingdom and Germany in the second quarter of 2013 and in Portugal and the U.S. in the first quarter of 2015. To date, the majority of the Company’s sales have been in Germany and the United Kingdom. The Company was able to launch in Germany without price restrictions, but continues to work with the statutory health insurance funds in Germany to streamline reimbursement for ILUVIEN. In October 2013, the United Kingdom’s National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination recommending ILUVIEN funding, taking into consideration a simple patient access scheme (PAS) for the treatment of pseudophakic eyes (eyes with an artificial lens) in chronic DME patients considered insufficiently responsive to available therapies. The Company began receiving orders for ILUVIEN from several National Health Service (NHS) facilities in January 2014 following the final technology appraisal guidance that was published in November 2013. Further, in February 2014, the Scottish Medicines Consortium, after completing its assessment and review of a similar simple PAS, announced that is has accepted ILUVIEN for restricted use within the NHS Scotland. In July 2013, the Transparency Commission (Commission de la Transparence or CT) of the French National Health Authority (Haute Autorite de Sante) issued a favorable opinion for the reimbursement and hospital listing of ILUVIEN by the French National Health Insurance for the treatment of chronic DME considered insufficiently responsive to available therapies. The Company continues to negotiate with the French authorities, but has not yet reached an agreement on price. In July 2014, the Company reached agreement with INFARMED, the marketing authorization body of the Portuguese Ministry of Health, for the pricing and reimbursement of ILUVIEN for the public sector in Portugal.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (interim financial statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article 10-01 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited interim condensed consolidated financial statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2014 and related notes included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 13, 2015. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year. Reclassifications Within the Operating expenses section of the unaudited Consolidated Statements of Operations for the three months ended March 31, 2014, the Company reclassified depreciation expense of $33,000 from general and administrative expenses to depreciation and amortization to conform to the current year presentation. In addition, the Company reclassified certain medical affairs support expenses of $128,000 from sales and marketing expenses to research, development and medical affairs expenses to conform to the current year presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2014. In addition, with the U.S. launch of ILUVIEN in the three months ended March 31, 2015, the Company adopted the policy set forth below. Revenue Recognition In the U.S., the Company sells ILUVIEN to a limited number of specialty distributors who in turn sell the product downstream to pharmacies and physician practices. Revenue from U.S. product sales is recorded upon sale to the specialty distributors net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. Government Rebates and Chargebacks: The Company estimates reductions to product sales for Medicaid and Veterans' Administration (VA) programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services (PHS), and other institutions (collectively qualified healthcare providers) represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., specialty distributors). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. Distribution-Related Fees: The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. Prompt Pay Discounts: No prompt pay discounts are currently offered to the Company's U.S. customers on sales. Product Returns: Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Depending on the circumstances, the Company may provide replacement products or cash credit for returns. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers to healthcare providers using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. Reporting Segments The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, the U.S. and International. Previously, the business was managed on an aggregate basis. As a result of the retrospective presentation and disclosure requirements under U.S. GAAP for changes in segment reporting, the Company is required to reflect the change in presentation and disclosure for all periods presented. As such, the Company has presented in Note 16, Segment Information, the financial results for the three months ended March 31, 2014 in the same manner as for the three months ended March 31, 2015. Research and Development Expenses Research and development expenses were $1,306,000 and $1,310,000 for the three months ended March 31, 2015 and 2014, respectively. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. Currently, the standard is scheduled to become effective for the first interim period within annual reporting periods beginning after December 15, 2016 for public entities, with no early adoption permitted. However, in April 2015, the FASB proposed a deferral of the effective date of the new revenue standard by one year, subject to the FASB’s due process requirement. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU.The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted and the standard is to be retrospectively applied to all periods presented upon adoption. The Company is still evaluating the potential impact of adopting this guidance on its financial statements.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following accounting policies relate primarily to the continuing operations of the Company: Use of Estimates in Financial Statements — The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and, as such, include amounts based on informed estimates and judgments of management. Actual results could differ from those estimates. Principles of Consolidation — The consolidated financial statements include the accounts of Alimera Sciences, Inc. and all wholly-owned subsidiaries. All significant inter-company balances have been eliminated in consolidation. Reclassifications — Within the operating expenses section of the Consolidated Statements of Operations for the year ended December 31, 2013, the Company reclassified depreciation expense of $138,000 from general and administrative expenses to depreciation and amortization to conform to the current year presentation. In addition, the Company reclassified certain medical affairs support expenses of $448,000 and $429,000 for the year ended December 31, 2014 and 2013, respectively, from sales and marketing expenses to research, development and medical affairs expenses. Cash and Cash Equivalents — Cash and cash equivalents include cash and highly liquid investments that are readily convertible into cash and have a maturity of 90 days or less when purchased. Generally, cash and cash equivalents held at financial institutions are in excess of federally insured limits. The Company limits its exposure to credit loss by placing its cash and cash equivalents in highly liquid investments with high quality financial institutions. Cash and cash equivalents were $76,697,000 and $12,628,000 at December 31, 2014 and 2013, respectively, with approximately 96.0% and 100.0% of these balances, respectively held in U.S. based financial institutions. Revenue Recognition — The Company recognizes revenue from its product sales when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. Title passes generally upon shipment or upon receipt by the customer depending on the agreement with the customer. Precise information regarding the receipt of product by the customer is not always readily available. In these cases, the Company estimates the date of receipt based upon shipping policies by geographic location. The Company's shipping policies require delivery within 24 hours of shipment in most instances. Taxes that are collected from customers and remitted to governmental authorities are not included in revenue. Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are generated through sales primarily to pharmacies, hospitals and wholesalers which began in 2013. The Company does not require collateral from its customers for accounts receivable. The carrying amount of accounts receivable is reduced by an allowance for doubtful accounts that reflects management's best estimate of the amounts that will not be collected. In addition to reviewing delinquent accounts receivable, management considers many factors in estimating its general allowance, including historical data, experience, customer types, credit worthiness, and economic trends. From time to time, management may adjust its assumptions for anticipated changes in any of those or other factors expected to affect collectability. Provisions for doubtful accounts are charged to operations at the time management determines these accounts may become uncollectable. The Company writes off accounts receivable when management determines they are uncollectable and credits payments subsequently received on such receivables to bad debt expense in the period received. There were accounts receivable write-offs of $21,000 for the year ended December 31, 2014 and no allowance for doubtful accounts at December 31, 2014. There were no accounts receivable write-offs for the year ended December 31, 2013 and no allowance for doubtful accounts at December 31, 2013. Inventory — Inventories are stated at the lower of cost or market with cost determined under the first in, first out (FIFO) method. Included in inventory costs are component parts, work-in-progress and finished goods. The Company relies on third party manufacturers for the production of all inventory and does not capitalize any internal costs. The Company periodically reviews inventories for excess, obsolete or expiring inventory and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated, or if there are any further determinations that inventory will not be marketable based on estimates of demand, additional inventory write-downs will be required. Intangible Assets — The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed, which approximates a straight-line basis, over the estimated periods benefited. The estimated useful life of the intangible asset is approximately thirteen years . Property and Equipment — Property and equipment are stated at cost. Additions and improvements are capitalized while repairs and maintenance are expensed. Depreciation is provided on the straight-line method over the useful life of the related assets beginning when the asset is placed in service. The estimated useful lives of the individual assets are as follows: furniture and fixtures and manufacturing equipment, five years ; office equipment and leasehold improvements, 29 months to five years ; and software, three years . Impairment — Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators of impairment are present, the Company evaluates the carrying amount of such assets in relation to the operating performance and future estimated undiscounted net cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. The assessment of the recoverability of assets will be impacted if estimated future operating cash flows are not achieved. Income Taxes — In accordance with the Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 740, Income Taxes , the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position; therefore, no ASC 740-10 liabilities have been recorded. The Company will recognize accrued interest and penalties related to unrecognized tax benefits, if any, as interest expense and income tax expense, respectively, in the consolidated statements of operations. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets as a result of the Company's history of operating losses, a valuation allowance has been established against the net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations. Research and Development Costs — Research and development costs are expensed as incurred. Research and development expenses were $7,594,000 and $3,904,000 for the year ended December 31, 2014 and 2013, respectively. Stock-Based Compensation — The Company has stock option plans which provide for grants of stock options to employees and directors to purchase shares of the Company’s common stock at exercise prices generally equal to the fair market values of such stock at the dates of grant. Compensation cost is recognized for all share-based awards based on the grant date fair value in accordance with the provisions of ASC 718, Compensation — Stock Compensation . The fair values for the options are estimated at the dates of grant using a Black-Scholes option-pricing model. Additionally, the Company sponsors an employee stock purchase plan under which employees may elect payroll withholdings to fund purchases of the Company’s stock at a discount. The Company estimates the fair value of the option to purchase shares of the Company’s common stock using the Black-Scholes valuation model and recognizes compensation expense in accordance with the provisions of ASC 718-50, Employee Share Purchase Plans . Derivative Financial Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase Series A convertible Preferred Stock or common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants were considered derivative instruments at issuance because the agreements provide for settlement in Series A Convertible Preferred Shares or common shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The warrant exercise price no longer can be adjusted at some point in the future. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of change in fair value of derivative warrant liability in the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At December 31, 2014 and 2013, these warrants represented the only outstanding derivative instruments issued or held by the Company. Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and current assets and liabilities approximate their fair value because of their short maturities. The weighted average interest rate of the Company’s notes payable approximates the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the note approximates the fair value. The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Translation Policy - The U.S. dollar is the functional currency for Alimera Sciences, Inc. The Euro is the functional currency for the majority of the Company's subsidiaries operating outside of the U.S. For Alimera Sciences, Inc., foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for non-monetary balance sheet accounts, which are remeasured at historical exchange rates. Revenue and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the non-monetary balance sheet amounts, which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in the statement of operations. The financial statements of the foreign subsidiaries whose functional currency is not the U.S. dollar, have been translated into U.S. dollars in accordance with ASC 830-30, Translation of Financial Statements . For the subsidiaries operating outside of the U.S. that are denominated in the Euro, assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income. Earnings (Loss) Per Share (EPS) — Basic EPS is calculated in accordance with ASC 260, Earnings per Share by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants, convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Years Ended December 31, 2014 2013 Series A convertible preferred stock 9,022,556 15,037,594 Series B convertible preferred stock 8,416,251 — Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 362,970 109,772 Stock options 7,681,256 7,566,437 Total 29,994,312 27,225,082 Reporting Segments — The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, the U.S. and International. Previously, the business was managed on an aggregate basis. During the second quarter of 2015, the CEO began managing the Company's operations as two operating business segments. As a result of the retrospective presentation and disclosure requirements under U.S. GAAP for changes in segment reporting, the Company is required to reflect the change in presentation and disclosure for all periods presented. As such, the Company has presented in Note 18, Segment Information, the financial results for the years ended December 31, 2014 and 2013. Promotional and Advertising Costs — Promotional and advertising costs are expensed as incurred. Recent Accounting Pronouncements — In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016 for public entities, with no early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In June 2014, the FASB issued ASU 2014-12, Compensation Stock - Compensation (Topic 718) . ASU 2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. It requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and follows existing accounting guidance for the treatment of performance conditions. The standard will be effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern. ASU 2014-15 provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements.

Factors Affecting Operations

Factors Affecting Operations	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
FACTORS AFFECTING OPERATIONS	FACTORS AFFECTING OPERATIONS To date, the Company has incurred negative cash flow from operations, and has accumulated a deficit of $323,048,000 from the Company’s inception through March 31, 2015 . As of March 31, 2015 , the Company had approximately $61,328,000 in cash and cash equivalents. The Company believes that it has sufficient funds available to fund its operations for the continued commercialization of ILUVIEN in Germany, the United Kingdom, Portugal and the U.S. The Company does not expect to generate positive cash flow from operations until 2016, if at all. The Company may seek to raise additional financing to fund its working capital needs associated with the commercialization of ILUVIEN in the U.S. If the Company is unable to raise additional financing, then it may adjust its commercial plans so that it can continue to operate with its existing cash resources. The accompanying interim condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company's negative cash flow from operations and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.	FACTORS AFFECTING OPERATIONS To date the Company has incurred recurring losses, negative cash flow from operations, and has accumulated a deficit of $313,255,000 from the Company’s inception through December 31, 2014 . As of December 31, 2014 , the Company had approximately $76,697,000 in cash and cash equivalents. The Company believes that it has sufficient funds available to fund its operations for the continued commercialization of ILUVIEN in Germany and the United Kingdom, and the launch of ILUVIEN in Portugal and the U.S. The Company does not expect the generation of positive cash flow from operations until 2016, at the earliest, if at all. The Company may seek to raise additional financing to fund its working capital needs associated with the commercialization of ILUVIEN in the U.S. If the Company is unable to raise additional financing, then it may adjust its commercial plans so that it can continue to operate with its existing cash resources. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company's recurring net losses, negative cash flow from operations and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Inventory

Inventory	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventory consisted of the following: March 31, 2015 December 31, 2014 (In thousands) Component parts (1) $ 136 $ 76 Work-in-process (2) 849 219 Finished goods 1,234 1,972 Total inventory 2,219 2,267 Inventory reserve (167 ) (533 ) Inventory — net $ 2,052 $ 1,734 (1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator. (2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.	INVENTORY Inventory consisted of the following: December 31, 2014 2013 (In thousands) Component parts (1) $ 76 $ 266 Work-in-process (2) 219 587 Finished goods 1,972 1,343 Total inventory 2,267 2,196 Inventory reserve (533 ) (410 ) Inventory — net $ 1,734 $ 1,786 (1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator. (2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by U.S. or EU regulatory authorities.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT Property and equipment consisted of the following: December 31, 2014 2013 (In thousands) Furniture and fixtures $ 367 $ 308 Office equipment 652 425 Software 601 439 Leasehold improvements 417 82 Manufacturing equipment 974 937 Total property and equipment 3,011 2,191 Less accumulated depreciation and amortization (1,358 ) (1,209 ) Property and equipment — net $ 1,653 $ 982 Depreciation and amortization expense associated with property and equipment totaled $149,000 and $138,000 for the years ended December 31, 2014 and 2013 , respectively.

Intangible Assets

Intangible Assets	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS As a result of the FDA's approval of the NDA for ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of $25,000,000 (the pSivida Milestone Payment) in October 2014 (see Note 8). The Company had no intangible assets prior to September 2014. The gross carrying amount of the intangible asset was $25,000,000 , which is being amortized over approximately 13 years from the acquisition date. The amortization expense related to the intangible asset was $479,000 for the three months ended March 31, 2015. The net book value of the intangible asset was $24,011,000 and $24,490,000 as of March 31 2015 and December 31, 2014, respectively. The estimated future amortization expense as of March 31, 2015 for the remaining periods in the next five years and thereafter is as follows (in thousands): Ending December 31 2015 $ 1,461 2016 1,940 2017 1,940 2018 1,940 2019 1,940 Thereafter 14,790 Total $ 24,011	INTANGIBLE ASSETS The Company had no intangible assets as of December 31, 2013. As a result of the FDA's approval of ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of $25,000,000 (the pSivida Milestone Payment) in October 2014 (see Note 8). The gross carrying amount of the intangible asset is $25,000,000 , which is being amortized over approximately 13 years from the acquisition date. The net book value of the intangible asset was $24,490,000 as of December 31, 2014, and amortization expense was $510,000 for the year ended December 31, 2014. The estimated remaining amortization as of December 31, 2014 is as follows (in thousands): Years Ending December 31 2015 $ 1,940 2016 1,940 2017 1,940 2018 1,940 2019 1,940 Thereafter 14,790 Total $ 24,490

Accrued Expenses

Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
ACCRUED EXPENSES	ACCRUED EXPENSES Accrued expenses consisted of the following: March 31, 2015 December 31, 2014 (In thousands) Accrued clinical investigator expenses $ 378 $ 309 Accrued compensation expenses 474 226 Other accrued expenses 857 419 Total accrued expenses $ 1,709 $ 954	ACCRUED EXPENSES Accrued expenses consisted of the following: December 31, 2014 2013 (In thousands) Accrued clinical investigator expenses $ 309 $ 562 Accrued other compensation expenses 226 106 Other accrued expenses 419 266 Total accrued expenses $ 954 $ 934

License Agreements

License Agreements	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure P Sivida Agreement Additional Information [Abstract]
LICENSE AGREEMENTS	LICENSE AGREEMENTS The Company entered into an agreement with pSivida for the use of fluocinolone acetonide (FAc) in pSivida’s proprietary delivery device in February 2005, which was subsequently amended in 2008. pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. The agreement with pSivida provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN. The Company’s license rights to pSivida’s proprietary delivery device could revert to pSivida if the Company were to (i) fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii) fail to cure other breaches of material terms of its agreement with pSivida within 30 days after notice of such breaches or such longer period (up to 90 days ) as may be reasonably necessary if the breach cannot be cured within such 30 -day period; (iii) file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days ; or (iv) notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida’s proprietary delivery device. The Company must share 20% of the net profits of ILUVIEN, determined on a cash basis, and 33% of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement, the Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the agreement, incurred prior to product profitability out of pSivida’s share of net profits. As of March 31, 2015 and December 31, 2014 , the Company was owed approximately $15,325,000 and $12,956,000 , respectively, in commercialization costs. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying interim condensed consolidated financial statements. As a result of the FDA's approval of the NDA for ILUVIEN in September 2014, the Company made the pSivida Milestone Payment of $25,000,000 in October 2014.	LICENSE AGREEMENTS The Company entered into an agreement with pSivida US, Inc. (pSivida) for the use of fluocinolone acetonide (FAc) in pSivida’s proprietary delivery device in February 2005, and a subsequent amendment in 2008. pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. The agreement with pSivida provides the Company with a worldwide exclusive license to develop and sell ILUVIEN. The Company’s license rights to pSivida’s proprietary delivery device could revert to pSivida if the Company were to (i) fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii) fail to cure other breaches of material terms of its agreement with pSivida within 30 days after notice of such breaches or such longer period (up to 90 days ) as may be reasonably necessary if the breach cannot be cured within such 30 -day period; (iii) file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days ; or (iv) notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida’s proprietary delivery device. Upon commercialization of ILUVIEN, the Company must share 20% of net profits, determined on a cash basis, and 33% of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement the Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the agreement, incurred prior to product profitability out of pSivida’s share of net profits, which is recovered as a reduction of future royalty payments. As of December 31, 2014 and 2013 , the Company was owed $15,144,000 and $12,219,000 , respectively, in commercialization costs. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying consolidated financial statements. As a result of the FDA's approval of the NDA for ILUVIEN in September 2014, the Company paid pSivida an additional milestone payment of $25,000,000 in October 2014.

Loan Agreements

Loan Agreements	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Text Block [Abstract]
TERM AND REVOLVING LOAN AGREEMENT	LOAN AGREEMENTS 2013 Loan Agreement In May 2013, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2013 Loan Agreement) with Silicon Valley Bank (SVB) to provide Limited with additional working capital for general corporate purposes. Under the 2013 Loan Agreement, SVB made a term loan (2013 Term Loan) in the principal amount of $5,000,000 to Limited and agreed to provide up to an additional $15,000,000 to Limited under a working capital line of credit (2013 Line of Credit). In April 2014, the 2013 Term Loan was repaid and the 2013 Line of Credit was terminated in connection with the 2014 Loan Agreement described below. Upon repayment of the 2013 Term Loan in April 2014, Limited paid SVB an outstanding loan balance prepayment penalty of $133,000 , and an early termination fee of $113,000 in connection with the termination of the 2013 Line of Credit in April 2014. 2014 Loan Agreement In April 2014, Limited entered into a loan and security agreement (2014 Loan Agreement) with Hercules Technology Growth Capital, Inc. (Hercules) providing for a term loan of up to $35,000,000 (2014 Term Loan). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of $10,000,000 to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay the 2013 Term Loan. Hercules made an additional advance of $25,000,000 to Limited in September 2014 following the approval of ILUVIEN by the FDA in September 2014 to fund the pSivida Milestone Payment. The 2014 Term Loan provides for interest only payments through November 2015. The interest only period may be extended until June 1, 2017 if the Company realizes certain revenue thresholds and no event of default has occurred under the 2014 Loan Agreement. As of March 31, 2015, the interest only period has not been extended. Interest on the 2014 Term Loan accrues at a floating per annum rate equal to the greater of (i) 10.90% , or (ii) the sum of (A) 7.65% , plus (B) the prime rate. Following the interest only period the term loan will be due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. In connection with the initial advance, Limited paid to Hercules a facility charge of $262,500 and incurred legal and other fees of approximately $383,000 . Limited incurred $375,000 in additional fees in connection with the second advance. If Limited repays the 2014 Term Loan prior to maturity, it will pay Hercules a prepayment penalty of 1.25% of the total principal amount repaid. Limited and the Company, on a consolidated basis with its other subsidiaries, also agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited’s obligations under the 2014 Loan Agreement and an increase to the applicable interest rate, and would permit Hercules to exercise remedies with respect to the collateral under the 2014 Loan Agreement. Limited’s obligations to Hercules are secured by a first priority security interest in substantially all of Limited’s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited’s intellectual property requiring Hercules' consent prior to the sale of such intellectual property. The Company and certain of the Company’s other subsidiaries are guarantors of the obligations of Limited to Hercules under the 2014 Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first priority security interest in substantially all of their respective assets excluding intellectual property. As of March 31, 2015, the Company, on a consolidated basis with its subsidiaries, was in compliance with the covenants of the 2014 Term Loan. In connection with Limited entering into the 2014 Loan Agreement, the Company entered into a warrant agreement with Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share. Sixty percent of the warrants were exercisable at the closing in April 2014 and the remaining forty percent became exercisable upon the funding of the additional $25,000,000 to Limited in September 2014. Fair Value of Debt The weighted average interest rates of the Company's notes payable approximate the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the notes approximated their fair value at March 31, 2015 and December 31, 2014.	LOAN AGREEMENTS 2010 Term Loan The Company entered into a loan and security agreement with Silicon Valley Bank (SVB) and MidCap Financial LLP (MidCap and together with SVB, the Lenders) in October 2010, which was subsequently amended in May 2011 (as amended, the 2010 Term Loan Agreement). Pursuant to the 2010 Term Loan Agreement, in October 2010 the Company borrowed an aggregate of $6,250,000 from the Lenders (the 2010 Term Loan). The 2010 Term Loan Agreement also provided for the ability to drawdown an additional $11,000,000 subject to FDA approval of the NDA for ILUVIEN by December 31, 2011, which was not obtained. In August 2011, the Company began repaying the outstanding principal under the 2010 Term Loan in 33 equal monthly installments plus interest at a rate of 11.5% . At maturity, the Company was also required to make an additional interest payment equal to 4% of the total amount borrowed. The Company paid to the Lenders an upfront fee of $62,500 upon execution of the 2010 Term Loan Agreement and an additional fee of $50,000 in connection with the May 2011 amendment. In accordance with ASC 470-50-40-17, Debt - Modifications and Extinguishments (ASC 470-50-40-17), the Company was amortizing the deferred financing costs on the 2010 Term Loan and the $50,000 modification fee over the remaining term of the 2010 Term Loan, as modified. In October 2010, in connection with entering into the 2010 Term Loan, the Company issued SVB a warrant to purchase up to 15,909 shares of the Company's common stock and MidCap a warrant to purchase up to 23,864 shares of the Company's common stock. Each of the warrants were exercisable upon issuance, had a per-share exercise price of $11.00 and a term of 10 years. The Company estimated the fair value of warrants granted using the Black-Scholes option pricing model to be $389,000 . The Company allocated a portion of the proceeds from the 2010 Term Loan to the warrants in accordance with ASC 470-20-25-2, Debt Instruments with Detachable Warrants . As a result, the Company recorded a discount of $366,000 which was amortized to interest expense using the effective interest method. The Lenders were also issued warrants to purchase up to an aggregate of 69,999 additional shares of the Company's common stock, which were exercisable only upon the drawdown of the additional $11,000,000 subject to FDA approval of the NDA for ILUVIEN by December 31, 2011, which was not obtained. In May 2013, the Company repaid all amounts owed to the Lenders under the 2010 Term Loan, including the final interest payment equal to 4% of the total amount borrowed, and a 1.0% prepayment penalty on the then outstanding principal owed to MidCap. In connection with the repayment of the 2010 Term Loan, and in accordance with ASC 470-50-40-17, the Company recognized a loss on early extinguishment of debt of $153,000 associated with the remaining unamortized deferred financing costs, unamortized discount associated with the Lenders' warrants, the final interest payment, the prepayment penalty and a lender fee and warrants associated with a new term loan. 2010 Revolving Loan Agreement In October 2010, the Company and SVB entered into a loan and security agreement, which was subsequently amended in May 2011 (as amended, the 2010 Revolving Loan Agreement), pursuant to which the Company obtained a secured revolving line of credit from SVB against eligible U.S. domestic accounts receivable with borrowing availability up to $20,000,000 . Upon entering into the 2010 Revolving Loan Agreement, the Company paid to SVB an upfront fee of $100,000 . In May 2013, the Company and SVB terminated the 2010 Revolving Loan Agreement. 2013 Loan Agreement In May 2013, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2013 Loan Agreement) with SVB to provide Limited with additional working capital for general corporate purposes. Under the 2013 Loan Agreement, SVB has made a term loan (2013 Term Loan) in the principal amount of $5,000,000 to Limited and has agreed to provide up to an additional $15,000,000 to Limited under a working capital line of credit (2013 Line of Credit). No advances were made at closing under the 2013 Line of Credit and no amounts were outstanding as of December 31, 2013. At December 31, 2013, the Company's ability to borrow under the 2013 Line of Credit was limited based on the Company's accounts receivable at the date as described below. The 2013 Term Loan provides for interest only payments for six months followed by 36 monthly payments of interest, plus principal. The Company made its first amortization payment on the 2013 Term Loan in December 2013. Interest on outstanding borrowings under the 2013 Term Loan is payable at the rate of 7.50% . Borrowings under the 2013 Line of Credit will be advanced at 80% of eligible accounts receivable as defined in the 2013 Loan Agreement. Interest is payable on the balance of eligible accounts financed at the rate of 2.75% above SVB's most recently announced “prime rate.” Limited is also required to pay SVB on a monthly basis an unused line fee equal to 0.25% per annum of the average unused portion of the 2013 Line of Credit during the preceding month. The maturity dates are June 30, 2015 with respect to the 2013 Line of Credit and October 31, 2016 with respect to the 2013 Term Loan. In connection with entering into the 2013 Loan Agreement, Limited paid SVB a facility fee of $25,000 . Additionally, the Company re-priced warrants to purchase an aggregate of up to 31,818 shares of the Company’s common stock previously issued to SVB in connection with the 2010 Term Loan; 15,909 of which were previously exercisable only upon the drawdown of the additional $11,000,000 of the 2010 Term Loan subject to FDA approval of the NDA for ILUVIEN by December 31, 2011. Upon re-pricing, each of the warrants was exercisable immediately at a per-share exercise price of $2.86 and had a remaining term of 7.4 years. The Company estimated the incremental fair value received by SVB using the Black-Scholes option pricing model to be $46,000 . In accordance with ASC 470-50-40-17, the Company expensed the facility fee and incremental value of the warrants associated with the 2013 Term Loan as part of the loss on early extinguishment of the 2010 Term Loan. Warrants to purchase up to an aggregate of 54,090 additional shares of the Company's common stock, which were exercisable only upon the drawdown of the additional $11,000,000 of the 2010 Term Loan subject to FDA approval of the NDA for ILUVIEN by December 31, 2011, which was not obtained, remain outstanding. In connection with the 2013 Line of Credit, Limited paid a commitment fee of $100,000 . In accordance with ASC 470-50-40-17, the Company capitalized the commitment fee and $49,000 of deferred financing costs remaining on the 2010 Revolving Loan Agreement as deferred financing costs, which are being amortized over the remaining term of the 2013 Line of Credit. Upon repayment of the 2013 Term Loan in April 2014, Limited paid SVB an outstanding loan balance prepayment penalty of $133,000 , and an early termination fee of $113,000 in connection with the termination of the 2013 Line of Credit in April 2014. 2014 Loan Agreement In April 2014, Limited entered into a loan and security agreement (2014 Loan Agreement) with Hercules Technology Growth Capital, Inc. (Hercules) providing for a term loan of up to $35,000,000 (2014 Term Loan). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of $10,000,000 to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay the 2013 Term Loan. Hercules made an additional advance of $25,000,000 to Limited in September 2014 following the approval of ILUVIEN by the FDA in September 2014 to fund the pSivida Milestone Payment. The 2014 Term Loan provides for interest only payments through November 2015. The interest only period may be extended until June 1, 2017 if the Company realizes certain revenue thresholds and no event of default has occurred under the 2014 Loan Agreement. As of December 31, 2014, the interest only period has not been extended. Interest on the 2014 Term Loan accrues at a floating per annum rate equal to the greater of (i) 10.90% , or (ii) the sum of (A) 7.65% , plus (B) the prime rate. Following the interest only period the term loan will be due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. In connection with the initial advance, Limited paid to Hercules a facility charge of $262,500 and incurred legal and other fees of approximately $383,000 . Limited incurred $375,000 in additional fees in connection with the second advance. If Limited repays the 2014 Term Loan prior to maturity, it will pay Hercules a prepayment penalty of 1.25% of the total principal amount repaid. Limited and the Company, on a consolidated basis with its other subsidiaries, also agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited’s obligations under the 2014 Loan Agreement and an increase to the applicable interest rate, and would permit Hercules to exercise remedies with respect to the collateral under the 2014 Loan Agreement. As of December 31, 2014, the Company, on a consolidated basis with its subsidiaries, was in compliance with the covenants of the 2014 Term Loan. Limited’s obligations to Hercules are secured by a first priority security interest in substantially all of Limited’s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited’s intellectual property requiring Hercules' consent prior to the sale of such intellectual property. The Company and certain of the Company’s other subsidiaries are guarantors of the obligations of Limited to Hercules under the 2014 Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first priority security interest in substantially all of their respective assets excluding intellectual property. In connection with Limited entering into the 2014 Loan Agreement, the Company entered into a warrant agreement with Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share. The Company estimated the fair value of warrants granted using the Black-Scholes option pricing model to be $1,349,000 . The Company allocated a portion of the proceeds from the 2014 Term Loan to the warrants in accordance with ASC 470-20-25-2, Debt Instruments with Detachable Warrants . As a result, the Company recorded a discount of $1,277,000 which is amortized to interest expense using the effective interest method. Sixty percent of the warrants were exercisable at the closing in April 2014 and the remaining forty percent became exercisable upon the funding of the additional $25,000,000 to Limited in September 2014. The weighted average interest rates of the Company's notes payable approximate the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the notes approximated their fair value at December 31, 2014 and 2013.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Term Note Payable — In April 2014, the Company entered into the 2014 Term Loan (Note 9). As of December 31, 2014 a schedule of future minimum principal payments under the Note Payable is as follows (in thousands): Years Ending December 31 2015 $ 1,023 2016 12,968 2017 14,487 2018 6,522 Total $ 35,000 As of December 31, 2014 , the Company had $324,000 accrued and unpaid interest payable on the Notes Payable. As of December 31, 2013 , the Company had no accrued and unpaid interest payable on its Notes Payable under the 2013 Loan Agreement. Operating Leases — The Company leases office space and equipment under non-cancelable agreements accounted for as operating leases. The leases generally require that the Company pay taxes, maintenance, and insurance. Management expects that in the normal course of business, leases that expire will be renewed or replaced by other leases. In August 2014, the Company signed a lease for office space in the U.S. through September 2021. In December 2014, Limited signed a lease for office space in the United Kingdom from December 17, 2014 to December 24, 2024, however the lease is cancellable after five years. The lease has a contingent escalation clause based on inflation beginning in 2020. The Company also leases office space in Germany and Portugal that can be renewed on an annual basis. At December 31, 2014 , a schedule by year of future minimum payments under operating leases is as follows (in thousands): Years Ending December 31 2015 $ 376 2016 509 2017 516 2018 525 2019 485 Thereafter 618 Total $ 3,029 Rent expense under all operating leases totaled approximately $521,000 and $576,000 for the years ended December 31, 2014 and 2013 , respectively. Capital Leases — The Company leases equipment under capital leases. The property and equipment is capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company’s incremental borrowing rate. At December 31, 2014 , a schedule by year of future minimum payments under capital leases, together with the present value of minimum lease payments, is as follows (in thousands): Years Ending December 31 2015 12 2016 9 Total 21 Less amount representing interest (2 ) Present value of minimum lease payments 19 Less current portion (11 ) Non-current portion $ 8 Property and equipment under capital leases, which are included in property and equipment (Note 5), consisted of the following: December 31, 2014 2013 (In thousands) Office equipment $ 33 $ 33 Less accumulated amortization (16 ) (5 ) Total $ 17 $ 28 Depreciation expense associated with office equipment under capital leases was $11,000 for each of the years ended December 31, 2014 and 2013 . Significant Agreements — In February 2010, the Company entered into an agreement with a third party manufacturer for the manufacture of the ILUVIEN implant, the assembly of the ILUVIEN applicator and packaging of the completed ILUVIEN commercial product. The Company is responsible for supplying the ILUVIEN applicator and the active pharmaceutical ingredient. In accordance with the terms of the agreement, the Company must order at least 80% of the ILUVIEN units required in the U.S., Canada and the EU from the third party manufacturer for an initial term of six years. The agreement has an initial six year term and will automatically renew for successive one year periods unless either party delivers written notice of non-renewal to the other at least 12 months prior to the end of the then current term. In March 2011, the Company entered into an agreement with a contract research organization (CRO) for clinical and data management services to be performed in connection with a physician utilization study which was being conducted to assess the safety and utility of the commercial version of the ILUVIEN applicator. For the years ended December 31, 2014 and 2013 , the Company incurred $16,000 and $690,000 , respectively, of expense associated with this agreement. At December 31, 2014 no amounts are recorded in outsourced services payable. At December 31, 2013 $30,000 is included in outsourced services payable. In February 2012, the Company engaged a consultant in connection with the Company's efforts to obtain the approval of ILUVIEN from the FDA. For the years ended December 31, 2014 and 2013, the Company recorded approximately $425,000 and $1,700,000 , respectively, in costs pertaining to consulting fees related to the Company's agreement with this consultant. In addition, the Company expensed a $2,000,000 success fee payable to this consultant which was payable upon the approval of our NDA by the FDA and paid in January 2015. At December 31, 2014, the $2,000,000 was included in accrued milestone payments. In November 2012, the Company entered into an agreement with Quintiles Commercial Europe Limited. Under the agreement, Quintiles Commercial Europe Limited and its affiliates (collectively, Quintiles Commercial) will provide certain services to the Company in connection with the commercialization of ILUVIEN in certain countries in Europe under subsequent project orders. Such services may include marketing, brand management, sales promotion and detailing, market access, pricing and reimbursement support, regulatory, medical science liaison and communications and/or other advisory services. As of December 31, 2014, the Company had entered into project orders with Quintiles Commercial for the provision of services in Germany, the United Kingdom and France. Under these project orders Quintiles Commercial, as of December 31, 2014, employed 16 persons fully dedicated to the Company. Quintiles Commercial also employed three persons partially dedicated to Alimera in Germany, the United Kingdom and France as of December 31, 2014. In the second half of 2014, the Company notified Quintiles Commercial that it would be terminating the project orders associated with Germany and France and transitioning the covered positions employed by Quintiles Commercial to its payroll. The Company expects to complete these transitions during the second quarter of 2015. In the first quarter of 2015, the Company notified Quintiles Commercial that it would be terminating the project orders associated with the United Kingdom and transitioning the covered positions employed by Quintiles Commercial to its payroll. The Company expects to complete this transition during the third quarter of 2015. As of December 31, 2104, under the existing project orders, the Company expects to incur approximately $4,400,000 in costs with Quintiles Commercial during 2015. For the year ended December 31, 2014 , the Company incurred $5,800,000 of expense associated with this agreement. At December 31, 2014 , $1,443,000 is included in outsourced services payable and $703,000 is included in prepaid expenses and other current assets. Employment Agreements — The Company is party to employment agreements with five executives. The agreements generally provide for annual salaries, bonuses, and benefits and for the “at-will” employment of such executives. Effective January 1, 2015, the Company was party to five agreements with salaries ranging from $309,000 to $504,000 . If any of the agreements are terminated by the Company without cause, or by the employee for good reason, as defined in the agreements, the Company will be liable for one year of salary and benefits. Certain other employees have general employment contracts which include stipulations regarding confidentiality, Company property, and miscellaneous items.

Preferred Stock

Preferred Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity [Abstract]
PREFERRED STOCK	PREFERRED STOCK Series A Convertible Preferred Stock On October 2, 2012, the Company closed its preferred stock financing in which it sold units consisting of 1,000,000 shares of Series A Convertible Preferred Stock and warrants to purchase 300,000 shares of Series A Convertible Preferred Stock for gross proceeds of $40,000,000 , prior to the payment of approximately $560,000 of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October 1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company’s common stock at any time at the option of the holder at the rate equal to $40.00 divided by $2.66 (Conversion Price). The initial Conversion Price is subject to adjustment based on certain customary price based anti-dilution adjustments. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i) the Company receives and publicly announces the approval by the FDA of the Company’s NDA for ILUVIEN and (ii) the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a) shares of common stock or (b) other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than $10.00 and that results in total gross proceeds to the Company of at least $30,000,000 . The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company's ability to declare or pay any dividend or distribution on any shares of capital stock. Each unit sold in the preferred stock financing included a warrant to purchase 0.30 shares of Series A Convertible Preferred Stock at an exercise price equal to $44.00 per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. At March 31, 2015 and December 31, 2014 , the fair market value of the warrants was estimated to be $13,592,000 and $16,098,000 , respectively. During the three months ended March 31, 2015 and 2014, the Company recorded gain of $2,506,000 and a loss of $13,130,000 , respectively, as a result of the change in fair value of the warrants. In April 2014, 2,255,639 shares of common stock were issued pursuant to the conversion of 150,000 shares of Series A Convertible Preferred Stock held by an investor. In September 2014, 3,759,398 shares of common stock were issued pursuant to the conversion of 250,000 shares of Series A Convertible Preferred Stock held by another investor. As of March 31, 2015, there were 600,000 shares of Series A Convertible Preferred Stock issued and outstanding. Series B Convertible Preferred Stock On December 12, 2014, the Company closed a preferred stock financing in which it sold 8,291.873 shares of Series B Convertible Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of $50,000,000 , prior to the payment of approximately $432,000 of related issuance costs. The Company issued an additional 124.378 shares of Series B Convertible Preferred Stock as a subscription premium to the purchasers. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into 1,000 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company’s existing Series A Convertible Preferred Stock, and senior to the Company’s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock do not have voting rights. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. The Company determined that the conversion option of the Preferred Shares represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of $750,000 as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.	PREFERRED STOCK Series A Convertible Preferred Stock On October 2, 2012, the Company closed its preferred stock financing in which it sold units consisting of 1,000,000 shares of Series A Convertible Preferred Stock and warrants to purchase 300,000 shares of Series A Convertible Preferred Stock for gross proceeds of $40,000,000 , prior to the payment of approximately $560,000 of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October 1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company’s common stock at any time at the option of the holder at the rate equal to $40.00 divided by the then current conversion price (Conversion Price). The initial Conversion Price of $2.91 of the Series A Convertible Preferred Stock was subject to adjustment to $3.16 or $2.66 based on the occurrence or non-occurrence of certain events relating to guidance from NICE regarding ILUVIEN, in addition to certain customary price based anti-dilution adjustments. A voluntary conversion by the holder prior to the determination of this adjustment is subject to a Conversion Price of $3.16 per share. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i) the Company receives and publicly announces the approval by the FDA of the Company’s NDA for ILUVIEN and (ii) the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a) shares of common stock or (b) other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than $10.00 and that results in total gross proceeds to the Company of at least $30,000,000 . The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company's ability to declare or pay any dividend or distribution on any shares of capital stock. On June 30, 2013, the Conversion Price was automatically adjusted to $2.66 . As a result of the adjustment to the Conversion Price, the value of the common stock underlying the Series A Convertible Preferred Stock at issuance exceeded the amount of the net proceeds allocated to the Series A Convertible Preferred Stock at issuance. Therefore, the Company recorded the contingent beneficial conversion feature of $4,950,000 as an increase in additional paid in capital. Because the Series A Convertible Preferred Stock was immediately convertible into common stock at the option of the holder on June 30, 2013, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series A Convertible Preferred Stock on that date. Each unit sold in the preferred stock financing included a warrant to purchase 0.30 shares of Series A Convertible Preferred Stock at an exercise price equal to $44.00 per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. At December 31, 2014 and 2013 the fair market value of the warrants was estimated to be $16,098,000 and $16,381,000 , respectively. The Company recorded a gain of $283,000 as a result of the change in fair value of the warrants during the year ended December 31, 2014. In April 2014, 2,255,639 shares of common stock were issued pursuant to the conversion of 150,000 shares of Series A Convertible Preferred Stock held by an investor. In September 2014, 3,759,398 shares of common stock were issued pursuant to the conversion of 250,000 shares of Series A Convertible Preferred Stock held by another investor. Series B Convertible Preferred Stock On December 12, 2014, the Company closed a preferred stock financing in which it sold 8,291.873 shares of Series B Convertible Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of $50,000,000 , prior to the payment of approximately $432,000 of related issuance costs. The Company has also agreed to issue the purchasers an additional 124.378 shares of Series B Convertible Preferred Stock as a subscription premium. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into 1,000 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company’s existing Series A Convertible Preferred Stock, and senior to the Company’s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock will not have voting rights. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. The Company determined that the conversion option of the Preferred Shares represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of $750,000 as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.

Loss Per Share (EPS)

Loss Per Share (EPS)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Loss Per Share (EPS)	LOSS PER SHARE (EPS) Basic EPS is calculated in accordance with ASC 260, Earnings per Share , by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Three Months Ended March 31, 2015 2014 Series A convertible preferred stock 9,022,556 15,037,593 Series B convertible preferred stock 8,416,251 — Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 362,970 77,954 Stock options 9,180,668 7,408,977 Total 31,493,724 27,035,803

Stock Incentive Plans

Stock Incentive Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK INCENTIVE PLANS	STOCK INCENTIVE PLANS Stock Option Plans During the three months ended March 31, 2015 and 2014, the Company recorded compensation expense related to stock options of approximately $1,070,000 and $925,000 , respectively. As of March 31, 2015, the total unrecognized compensation cost related to non-vested stock options granted was $10,776,000 and is expected to be recognized over a weighted average period of 3.21 years . The following table presents a summary of stock option activity for the three months ended March 31, 2015 and 2014: Three Months Ended March 31, 2015 2014 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 7,681,256 $ 3.03 7,566,438 $ 2.74 Grants 1,598,500 5.49 — — Forfeitures (33,140 ) 4.64 — — Exercises (65,948 ) 1.90 (157,461 ) 1.82 Options outstanding at period end 9,180,668 3.46 7,408,977 2.76 Options exercisable at period end 4,750,021 3.18 3,584,416 3.14 Weighted average per share fair value of options granted during the period $ 4.29 $ — The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of March 31, 2015 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 9,180,668 $ 3.46 7.37 years $ 18,023 Exercisable 4,750,021 3.18 5.92 years 11,466 Outstanding, vested and expected to vest 8,549,361 3.42 7.24 years 17,241 The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of December 31, 2014 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 7,681,256 $ 3.03 7.05 years $ 21,710 Exercisable 4,452,274 3.17 5.87 years 12,887 Outstanding, vested and expected to vest 7,258,603 3.04 6.95 years 20,574 Employee Stock Purchase Plan During the three months ended March 31, 2015 and 2014, the Company recorded compensation expense related to its employee stock purchase plan of approximately $11,000 and $8,000 , respectively.	STOCK INCENTIVE PLANS The Company has stock option and stock incentive plans which provide for grants of shares to employees and grants of options to employees and directors to purchase shares of the Company’s common stock at exercise prices generally equal to the fair values of such stock at the dates of grant. Options granted to employees typically become exercisable over a four -year vesting period and have a ten -year contractual term. Initial options granted to directors typically vest over a four -year period and have a ten -year contractual term. Annual option grants to directors typically vest immediately and have a ten -year contractual term. Upon the exercise of stock options, the Company may issue the required shares out of authorized but unissued common stock or out of treasury stock at management’s discretion. A summary of stock option transactions under the plans are as follows: Years Ended December 31, 2014 2013 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 7,566,438 $ 2.74 5,493,079 $ 2.67 Grants 716,500 5.56 2,630,000 2.71 Forfeitures (210,375 ) 3.10 (513,059 ) 1.96 Exercises (391,307 ) 1.97 (43,582 ) 1.64 Options outstanding at year end 7,681,256 3.03 7,566,438 2.74 Options exercisable at year end 4,452,274 3.17 3,304,981 3.09 Weighted average per share fair value of options granted during the year $ 4.43 $ 2.14 The following table provides additional information related to outstanding stock options, fully vested stock options, and stock options expected to vest as of December 31, 2014 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 7,681,256 $ 3.03 7.05 years $ 21,710 Exercisable 4,452,274 3.17 5.87 years 12,887 Outstanding, vested and expected to vest 7,258,603 3.04 6.95 years 20,574 The Company estimated the fair value of options granted using the Black-Scholes option pricing model. Use of a valuation model requires the Company to make certain assumptions with respect to selected model inputs. Changes in these input variables would affect the amount of expense associated with equity-based compensation. Expected volatility is based on the historical volatility of the Company's common shares over the expected term of the stock option grant. To estimate the expected term, the Company utilizes the “simplified” method for “plain vanilla” options as discussed within the Securities and Exchange Commission’s Statement of Accounting Bulletin 107. The Company intends to utilize the simplified method for the foreseeable future until more detailed information about exercise behavior will be more widely available. The risk-free interest rate is based on U.S. Treasury Daily Treasury Yield Curve Rates corresponding to the expected life assumed at the date of grant. Dividend yield is zero as there are no payments of dividends made or expected. The weighted-average assumptions used for option grants were as follows: Years Ended December 31, 2014 2013 Risk-free interest rate 1.79 % 1.73 % Volatility factor 102.54 % 100.76 % Grant date fair value of common stock $ 4.43 $ 2.14 Weighted-average expected life 5.89 years 5.92 years Assumed forfeiture rate 10.00 % 10.00 % Employee stock-based compensation expense related to stock options recognized under ASC 718 was as follows: Years Ended December 31, 2014 2013 (In thousands) Sales and marketing $ 548 $ 366 Research, development and medical affairs 981 504 General and administrative 2,274 1,586 Total employee stock-based compensation expense $ 3,803 $ 2,456 As of December 31, 2014, there was approximately $6,101,000 of total unrecognized compensation cost related to outstanding stock option awards that will be recognized over a weighted average period of 2.7 years. The total fair value of shares vested during the year ended December 31, 2014 was approximately $3,833,000 . The total estimated fair value of options granted during the years ended December 31, 2014 and 2013 was $3,177,000 and $5,618,000 , respectively. The total estimated intrinsic value of options exercised during the years ended December 31, 2014 and 2013 was $1,710,000 and $79,000 , respectively. As of December 31, 2014, the Company was authorized to grant options to purchase up to an additional 774,723 shares under the 2010 Equity Incentive Plan. The Company’s 2010 Plan provides for annual increases in the number of shares available for issuance thereunder on the first day of each fiscal year equal to the least of: (1) 2,000,000 shares of our common stock; (2) 4% of the shares of common stock outstanding at that time; and (3) such other amount as our board of directors may determine. On January 1, 2015, an additional 1,772,814 shares became available for future issuance under the 2010 Plan. These additional shares from the annual increase under the 2010 Plan are not included in the foregoing discussion. The following table summarizes outstanding and exercisable options at December 31, 2014 : Options Outstanding Options Exercisable Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable Weighted Average Remaining Contractual Life $1.33 - $1.99 3,408,452 6.32 2,309,473 5.61 $2.00 - $2.99 2,442,796 7.70 1,020,648 5.98 $3.00 - $4.99 449,564 6.26 345,813 5.43 $5.00 - $10.99 1,019,794 8.71 415,690 7.46 $11.00 - $11.91 360,650 5.78 360,650 5.78 7,681,256 4,452,274

Common Stock Warrants

Common Stock Warrants	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity [Abstract]
COMMON STOCK WARRANTS	COMMON STOCK In January 2014, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company sold an aggregate of 6,250,000 shares of its common stock at a purchase price of $6.00 per share. Gross proceeds from the offering were $37,500,000 prior to the payment of approximately $2,389,000 of related issuance costs. Proceeds from the private placement were used for general corporate and working capital purposes. In April 2014, 2,255,639 shares of common stock were issued pursuant to the conversion of 150,000 shares of Series A Convertible Preferred Stock held by an investor. In September 2014, 3,759,398 shares of common stock were issued pursuant to the conversion of 250,000 shares of Series A Convertible Preferred Stock held by another investor.	COMMON STOCK WARRANTS The Company has issued warrants to purchase common stock to various members of the board of directors, third-parties for services, and lenders. Total warrants to purchase common stock issued and exercisable were 362,970 and 109,772 at December 31, 2014 and 2013 , respectively. At December 31, 2014, the exercise prices ranged from $6.14 to $11.00 per share. The warrants are exercisable for a period between 5 and 10 years from the issuance date. Warrants to purchase 39,773 of the Company’s common stock were granted to the Lenders during the year ended December 31, 2010 in connection the issuance of the 2010 Term Loan (Note 9). The Lenders also held warrants to purchase an aggregate of up to 69,999 shares of the Company’s common stock, which were exercisable only upon the drawdown of the additional $11,000,000 subject to FDA approval of the NDA for ILUVIEN by December 31, 2011, which was not obtained. In May 2013, in connection with the 2013 Loan Agreement, the Company re-priced warrants to purchase an aggregate of up to 31,818 shares of the Company's common stock previously issued to SVB in connection with the 2010 Term Loan; 15,909 of which were previously exercisable only upon the drawdown of the additional $11,000,000 of the 2010 Term Loan subject to FDA approval of the NDA for ILUVIEN by December 31, 2011. Upon re-pricing, each of the warrants was exercisable immediately at a per-share exercise price of $2.86 and had a remaining term of 7.4 years. SVB exercised 31,818 of their warrants in the first quarter of 2014 in which the Company issued 18,092 shares of common stock as part of a cashless exercise. In connection with Limited entering into the 2014 Loan Agreement (Note 9), the Company entered into a warrant agreement with Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share. Sixty percent of the warrants were exercisable at the closing in April 2014 and the remaining forty percent became exercisable upon the funding of the additional $25,000,000 to Limited in September 2014.

Concentration and Credit Risk

Concentration and Credit Risk	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND CREDIT RISK	CONCENTRATIONS AND CREDIT RISK There were no customers that accounted for more than 10% of revenue for the year ended December 31, 2014 or accounts receivable at December 31, 2014. There were two pharmacy customers that comprised $314,000 of the Company’s accounts receivable at December 31, 2013. These same two customers accounted for approximately 23% of the Company's total consolidated revenues for the year ended December 31, 2013. For the years ended December 31, 2014 and 2013, one vendor comprised of approximately 14% and two vendors comprised approximately 42% of the Company’s total purchases, respectively.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates. The Company’s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company’s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred. The Company’s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company’s effective tax rate for the three months ended March 31, 2015 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions are more likely than not to be sustained on audit ; therefore, no ASC 740-10 liabilities and no related penalties and interest have been recorded. The Company does not anticipate any material changes to its uncertain tax positions within the next 12 months. Tax years since 2003 remain subject to examination in Georgia, Tennessee, and at the federal level. The time period is longer than the standard statutory 3-year period due to net operating losses (NOLs) from 2003 being available for utilization. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Tax years since 2012 remain subject to examination in the United Kingdom and the Netherlands. Tax years since 2013 remain subject to examination in Germany. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the entire net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact its financial position and results of operations. At December 31, 2014, the Company had federal NOL carry-forwards of approximately $87,380,000 and state NOL carry-forwards of approximately $70,840,000 available to reduce future income. The Company's federal NOL carry-forwards remain fully reserved as of March 31, 2015. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2034 and the state NOL carry-forwards will expire at various dates between 2020 and 2034. The Company's NOL carry-forwards may be subject to annual limitations under Internal Revenue Code (IRC) Section 382 (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership, including its IPO, have occurred that would limit its ability to utilize a portion of the Company's NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, the Company may be subject to annual limitations on the use of these NOL carry-forwards under IRC Section 382 (or comparable provisions of state law). As of December 31, 2014, the Company had cumulative book losses in foreign subsidiaries of $42,795,000 . The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company has not recorded a deferred tax liability related to excess of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.	INCOME TAXES The components of net loss before taxes are as follows: Years Ended December 31, 2014 2013 (In thousands) United States $ (12,102 ) $ (29,303 ) Foreign (23,458 ) (16,926 ) Loss before provision for income taxes $ (35,560 ) $ (46,229 ) In accordance with ASC 740, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against the net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. The provision for income taxes consists of the following components: Years Ended December 31, 2014 2013 (In thousands) Current benefit (expense): Federal $ — $ — State — — Foreign 174 — Current income tax expense $ 174 $ — Years Ended December 31, 2014 2013 (In thousands) Deferred benefit (expense): Federal $ 3,050 $ (18,565 ) State 355 (2,162 ) Foreign (3,161 ) 3,160 244 (17,567 ) Valuation allowance (244 ) 17,567 Deferred income tax (benefit) expense $ — $ — Worldwide net deferred tax assets and liabilities are as follows: December 31, 2014 2013 Deferred tax assets (current and non-current) (In thousands) Depreciation and amortization $ 8 $ 34 Other deferred tax assets 3,305 1,906 NOL carry-forwards 32,191 33,454 Research and development costs 5,167 6,142 Collaboration agreement receivable reserves 5,749 4,638 Valuation allowance (46,400 ) (46,156 ) Total deferred tax assets $ 20 $ 18 Deferred tax liabilities (current and non-current) Unrealized foreign currency gains $ (20 ) $ (18 ) Other deferred tax liabilities — — Total deferred tax liabilities (20 ) (18 ) Net deferred tax assets and deferred tax liabilities (current and non-current) $ — $ — In Accordance with ASC 740-10-45-4, the Company presents below the current and non-current components of the Company's deferred tax assets and deferred tax liabilities. The Company has applied the jurisdictional netting requirements of ASC 740-10-45-5 to allocate the valuation allowance between current and non-current deferred tax assets on a jurisdictional basis. The current deferred tax liability and the non-current deferred tax asset disclosed below are attributable to the United States. Deferred tax positions in each foreign jurisdiction net to zero on both a current and non-current basis. Years Ended December 31, 2014 2013 (In thousands) Current deferred tax liability $ (20 ) $ (18 ) Non-current deferred tax asset 20 18 A reconciliation from the federal statutory rate to the total provision for income taxes is as follows: Years Ended December 31, 2014 2013 Amount Percent Amount Percent Federal tax benefit at statutory rate $ (12,150 ) 34.0 % $ (15,718 ) 34.0 % State tax — net of federal benefit (479 ) 1.3 (1,160 ) 2.5 Permanent items and other 331 (0.9 ) 31,851 (68.9 ) Prior period transfer pricing adjustments 3,502 (9.8 ) — — Foreign rate differential 8,190 (22.9 ) 2,594 (5.6 ) Other 536 (1.5 ) — — Change in valuation allowance 244 (0.7 ) (17,567 ) 38.0 Total tax benefit (expense) $ 174 (0.5 )% $ — — % The significant increase for the current year in the effect of permanent differences is caused by intercompany transactions between Alimera Sciences, Inc. and its subsidiaries in the prior year. For financial statement purposes, the transaction eliminates in consolidation. For income tax purposes, the transaction resulted in taxable income in the United States which was offset by net operating losses. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions are more likely than not of being sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position; therefore, no ASC 740-10 liabilities and no related penalties and interest have been recorded. The Company does not anticipate any material changes to its uncertain tax positions within the next 12 months. Tax years since from 2011 to 2014 remain subject to examination in Georgia, Tennessee, and on the federal level, with the exception of the assessment of NOL carry-forwards available for utilization which can be examined for all years since 2003. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the entire net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations. At December 31, 2014 and 2013 , the Company had federal net operating loss (NOL) carry-forwards of approximately $87,380,000 and $82,380,000 and state NOL carry-forwards of approximately $70,840,000 , and $65,840,000 respectively, that are available to reduce future income unless otherwise taxable. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2034 and the state NOL carry-forwards will expire at various dates between 2020 and 2034. NOL carry-forwards may be subject to annual limitations under Internal Revenue Code Section 382 (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership, including its IPO, have occurred that would limit the Company’s ability to utilize a portion of its NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, it may be subject to annual limitations on the use of these NOL carry-forwards under Internal Revenue Code (IRC), Section 382 (or comparable provisions of state law). The issuance of the Series A Convertible Preferred Stock on October 2, 2012 constituted such a change in ownership. As a result of this change in ownership, the Company performed a formal analysis in connection with IRC Section 382 and determined that approximately $13,700,000 of its NOLs generated prior to the change in ownership could not be utilized in the future. As of December 31, 2014, the Company had cumulative book losses in foreign subsidiaries of $42,795,000 . The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company does not expect to record deferred tax liabilities in the future related to excesses of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.

Fair Value

Fair Value	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE The Company applies ASC 820, Fair Value Measurements , in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows: Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. There have been no changes in the methodologies used at March 31, 2015 and December 31, 2014. The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: March 31, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 4,510 $ — $ — $ 4,510 Assets measured at fair value $ 4,510 $ — $ — $ 4,510 Liabilities: Derivative warrant liability (2) $ — $ 13,592 $ — $ 13,592 Liabilities measured at fair value $ — $ 13,592 $ — $ 13,592 December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 65,509 $ — $ — $ 65,509 Assets measured at fair value $ 65,509 $ — $ — $ 65,509 Liabilities: Derivative warrant liability (2) $ — $ 16,098 $ — $ 16,098 Liabilities measured at fair value $ — $ 16,098 $ — $ 16,098 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.	FAIR VALUE The Company applies ASC 820, Fair Value Measurements in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows: Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. There have been no changes in the methodologies used at December 31, 2014 and 2013. The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 65,509 $ — $ — $ 65,509 Assets measured at fair value $ 65,509 $ — $ — $ 65,509 Liabilities: Derivative warrant liability (2) $ — $ 16,098 $ — $ 16,098 Liabilities measured at fair value $ — $ 16,098 $ — $ 16,098 December 31, 2013 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 6,944 $ — $ — $ 6,944 Assets measured at fair value $ 6,944 $ — $ — $ 6,944 Liabilities: Derivative warrant liability (2) $ — $ 16,381 $ — $ 16,381 Liabilities measured at fair value $ — $ 16,381 $ — $ 16,381 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS The Company has a salary deferral 401(k) plan which covers substantially all U.S. employees of the Company. The Company matches participant contributions subject to certain plan limitations. Compensation expense associated with the Company’s matching plan totaled $107,000 and $95,000 for the years ended December 31, 2014 and 2013 , respectively. The Company may also make an annual discretionary profit-sharing contribution. No such discretionary contributions were made during the years ended December 31, 2014 and 2013 , respectively. In April 2010, the Company established an Employee Stock Purchase Plan (the “Purchase Plan”). Under the Company’s Purchase Plan, eligible employees can participate and purchase common stock semi-annually through accumulated payroll deductions. The Purchase Plan is administered by the Company’s board of directors or a committee appointed by the Company’s board of directors. Under the Purchase Plan eligible employees may purchase stock at 85% of the lower of the fair market value of a share of Common Stock on the offering date or the exercise date. The Purchase Plan provides for two six -month purchase periods generally starting on the first trading day on or after October 31 and April 30 of each year. Eligible employees may contribute up to 15% of their eligible compensation. A participant may purchase a maximum of 2,500 shares of common stock per purchase period. The value of the shares purchased in any calendar year may not exceed $25,000 . The Purchase Plan was effective upon the completion of the Company’s IPO, at which time a total of 494,422 shares of the Company’s common stock were made available for sale. As of January 1 of each year, starting in 2011, the reserve will automatically be restored to the original level. A total of 34,915 and 26,123 shares of the Company’s common shares were acquired through the Purchase Plan during the years ended December 31, 2014 and 2013 , respectively. As such, on January 1, 2015 and 2014, respectively, an additional 34,915 and 26,123 shares became available for future issuance under the Purchase Plan. In accordance with ASC 718-50, the ability to purchase stock at 85% of the lower of the fair market value of a share of Common Stock on the offering date or the exercise date represents an option. The Company estimates the fair value of such options at the inception of each offering period using the Black-Scholes valuation model. In connection with the Purchase Plan, the Company recorded $47,000 and $21,000 of compensation expense for the years ended December 31, 2014 and 2013 , respectively.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The following table presents a summary of the Company's reporting segments for the years ended December 31, 2014 and 2013: Year Ended December 31, 2014 Year Ended December 31, 2013 U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 17 $ 8,406 $ 8,423 $ — $ 1,872 $ 1,872 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1 ) (1,441 ) (1,442 ) — (1,863 ) (1,863 ) GROSS PROFIT 16 6,965 6,981 — 9 9 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 5,400 6,411 11,811 4,110 4,748 8,858 GENERAL AND ADMINISTRATIVE EXPENSES 7,496 4,875 12,371 5,048 4,427 9,475 SALES AND MARKETING EXPENSES 4,704 10,383 15,087 891 15,051 15,942 DEPRECIATION AND AMORTIZATION 657 2 659 138 — 138 OPERATING EXPENSES 18,257 21,671 39,928 10,187 24,226 34,413 NET LOSS FROM OPERATIONS (18,241 ) (14,706 ) (32,947 ) (10,187 ) (24,217 ) (34,404 ) OTHER INCOME AND EXPENSES, NET (2,789 ) (11,825 ) NET (LOSS) INCOME BEFORE TAXES $ (35,736 ) $ (46,229 ) SEGMENT INFORMATION The following table presents a summary of the Company's reporting segments for the three months ended March 31, 2015 and 2014: Three Months Ended March 31, 2015 Three Months Ended U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 2,443 $ 1,495 $ 3,938 $ — $ 2,084 $ 2,084 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (138 ) (145 ) (283 ) — (564 ) (564 ) GROSS PROFIT 2,305 1,350 3,655 — 1,520 1,520 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,379 1,950 3,329 1,150 1,604 2,754 GENERAL AND ADMINISTRATIVE EXPENSES 2,188 1,431 3,619 1,651 1,243 2,894 SALES AND MARKETING EXPENSES 4,880 2,249 7,129 361 2,922 3,283 DEPRECIATION AND AMORTIZATION 558 14 572 33 — 33 OPERATING EXPENSES 9,005 5,644 14,649 3,195 5,769 8,964 NET LOSS FROM OPERATIONS (6,700 ) (4,294 ) (10,994 ) (3,195 ) (4,249 ) (7,444 ) OTHER INCOME AND EXPENSES, NET 1,270 (13,315 ) NET (LOSS) INCOME BEFORE TAXES $ (9,724 ) $ (20,759 )

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates in Financial Statements		Use of Estimates in Financial Statements — The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and, as such, include amounts based on informed estimates and judgments of management. Actual results could differ from those estimates.
Principles of Consolidation		Principles of Consolidation — The consolidated financial statements include the accounts of Alimera Sciences, Inc. and all wholly-owned subsidiaries. All significant inter-company balances have been eliminated in consolidation.
Reclassifications		Reclassifications — Within the operating expenses section of the Consolidated Statements of Operations for the year ended December 31, 2013, the Company reclassified depreciation expense of $138,000 from general and administrative expenses to depreciation and amortization to conform to the current year presentation.
Cash and Cash Equivalents		Cash and Cash Equivalents — Cash and cash equivalents include cash and highly liquid investments that are readily convertible into cash and have a maturity of 90 days or less when purchased. Generally, cash and cash equivalents held at financial institutions are in excess of federally insured limits. The Company limits its exposure to credit loss by placing its cash and cash equivalents in highly liquid investments with high quality financial institutions
Revenue Recognition	Revenue Recognition In the U.S., the Company sells ILUVIEN to a limited number of specialty distributors who in turn sell the product downstream to pharmacies and physician practices. Revenue from U.S. product sales is recorded upon sale to the specialty distributors net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. Government Rebates and Chargebacks: The Company estimates reductions to product sales for Medicaid and Veterans' Administration (VA) programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services (PHS), and other institutions (collectively qualified healthcare providers) represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., specialty distributors). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. Distribution-Related Fees: The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. Prompt Pay Discounts: No prompt pay discounts are currently offered to the Company's U.S. customers on sales. Product Returns: Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Depending on the circumstances, the Company may provide replacement products or cash credit for returns. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers to healthcare providers using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.	Revenue Recognition — The Company recognizes revenue from its product sales when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. Title passes generally upon shipment or upon receipt by the customer depending on the agreement with the customer. Precise information regarding the receipt of product by the customer is not always readily available. In these cases, the Company estimates the date of receipt based upon shipping policies by geographic location. The Company's shipping policies require delivery within 24 hours of shipment in most instances.
Accounts Receivable and Allowance for Doubtful Accounts		Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are generated through sales primarily to pharmacies, hospitals and wholesalers which began in 2013. The Company does not require collateral from its customers for accounts receivable. The carrying amount of accounts receivable is reduced by an allowance for doubtful accounts that reflects management's best estimate of the amounts that will not be collected. In addition to reviewing delinquent accounts receivable, management considers many factors in estimating its general allowance, including historical data, experience, customer types, credit worthiness, and economic trends. From time to time, management may adjust its assumptions for anticipated changes in any of those or other factors expected to affect collectability. Provisions for doubtful accounts are charged to operations at the time management determines these accounts may become uncollectable. The Company writes off accounts receivable when management determines they are uncollectable and credits payments subsequently received on such receivables to bad debt expense in the period received.
Inventory		Inventory — Inventories are stated at the lower of cost or market with cost determined under the first in, first out (FIFO) method. Included in inventory costs are component parts, work-in-progress and finished goods. The Company relies on third party manufacturers for the production of all inventory and does not capitalize any internal costs. The Company periodically reviews inventories for excess, obsolete or expiring inventory and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated, or if there are any further determinations that inventory will not be marketable based on estimates of demand, additional inventory write-downs will be required
Intangible Assets		Intangible Assets — The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed, which approximates a straight-line basis, over the estimated periods benefited. The estimated useful life of the intangible asset is approximately thirteen years .
Long-Lived Assets		Property and Equipment — Property and equipment are stated at cost. Additions and improvements are capitalized while repairs and maintenance are expensed. Depreciation is provided on the straight-line method over the useful life of the related assets beginning when the asset is placed in service. The estimated useful lives of the individual assets are as follows: furniture and fixtures and manufacturing equipment, five years ; office equipment and leasehold improvements, 29 months to five years ; and software, three years .
Impairment		Impairment — Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators of impairment are present, the Company evaluates the carrying amount of such assets in relation to the operating performance and future estimated undiscounted net cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. The assessment of the recoverability of assets will be impacted if estimated future operating cash flows are not achieved.
Income Taxes		Income Taxes — In accordance with the Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 740, Income Taxes , the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position; therefore, no ASC 740-10 liabilities have been recorded. The Company will recognize accrued interest and penalties related to unrecognized tax benefits, if any, as interest expense and income tax expense, respectively, in the consolidated statements of operations. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets as a result of the Company's history of operating losses, a valuation allowance has been established against the net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations.
Research and Development Costs		Research and Development Costs — Research and development costs are expensed as incurred.
Stock-Based Compensation		Stock-Based Compensation — The Company has stock option plans which provide for grants of stock options to employees and directors to purchase shares of the Company’s common stock at exercise prices generally equal to the fair market values of such stock at the dates of grant. Compensation cost is recognized for all share-based awards based on the grant date fair value in accordance with the provisions of ASC 718, Compensation — Stock Compensation . The fair values for the options are estimated at the dates of grant using a Black-Scholes option-pricing model. Additionally, the Company sponsors an employee stock purchase plan under which employees may elect payroll withholdings to fund purchases of the Company’s stock at a discount. The Company estimates the fair value of the option to purchase shares of the Company’s common stock using the Black-Scholes valuation model and recognizes compensation expense in accordance with the provisions of ASC 718-50, Employee Share Purchase Plans .
Derivative Financial Instruments		Derivative Financial Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase Series A convertible Preferred Stock or common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants were considered derivative instruments at issuance because the agreements provide for settlement in Series A Convertible Preferred Shares or common shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The warrant exercise price no longer can be adjusted at some point in the future. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of change in fair value of derivative warrant liability in the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At December 31, 2014 and 2013, these warrants represented the only outstanding derivative instruments issued or held by the Company.
Fair Value of Financial Instruments		Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and current assets and liabilities approximate their fair value because of their short maturities. The weighted average interest rate of the Company’s notes payable approximates the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the note approximates the fair value. The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.
Foreign Currency Translation		Translation Policy - The U.S. dollar is the functional currency for Alimera Sciences, Inc. The Euro is the functional currency for the majority of the Company's subsidiaries operating outside of the U.S. For Alimera Sciences, Inc., foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for non-monetary balance sheet accounts, which are remeasured at historical exchange rates. Revenue and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the non-monetary balance sheet amounts, which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in the statement of operations. The financial statements of the foreign subsidiaries whose functional currency is not the U.S. dollar, have been translated into U.S. dollars in accordance with ASC 830-30, Translation of Financial Statements . For the subsidiaries operating outside of the U.S. that are denominated in the Euro, assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income.
Earnings (Loss) Per Share (EPS)		Earnings (Loss) Per Share (EPS) — Basic EPS is calculated in accordance with ASC 260, Earnings per Share by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants, convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive.
Reporting Segments	Reporting Segments The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, the U.S. and International. Previously, the business was managed on an aggregate basis. As a result of the retrospective presentation and disclosure requirements under U.S. GAAP for changes in segment reporting, the Company is required to reflect the change in presentation and disclosure for all periods presented. As such, the Company has presented in Note 16, Segment Information, the financial results for the three months ended March 31, 2014 in the same manner as for the three months ended March 31, 2015.	Reporting Segments — The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, the U.S. and International. Previously, the business was managed on an aggregate basis. During the second quarter of 2015, the CEO began managing the Company's operations as two operating business segments. As a result of the retrospective presentation and disclosure requirements under U.S. GAAP for changes in segment reporting, the Company is required to reflect the change in presentation and disclosure for all periods presented. As such, the Company has presented in Note 18, Segment Information, the financial results for the years ended December 31, 2014 and 2013.
Promotional and Advertising Costs		Promotional and Advertising Costs — Promotional and advertising costs are expensed as incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. Currently, the standard is scheduled to become effective for the first interim period within annual reporting periods beginning after December 15, 2016 for public entities, with no early adoption permitted. However, in April 2015, the FASB proposed a deferral of the effective date of the new revenue standard by one year, subject to the FASB’s due process requirement. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU.The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted and the standard is to be retrospectively applied to all periods presented upon adoption. The Company is still evaluating the potential impact of adopting this guidance on its financial statements.	Recent Accounting Pronouncements — In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016 for public entities, with no early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In June 2014, the FASB issued ASU 2014-12, Compensation Stock - Compensation (Topic 718) . ASU 2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. It requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and follows existing accounting guidance for the treatment of performance conditions. The standard will be effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, with early adoption permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern. ASU 2014-15 provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Three Months Ended March 31, 2015 2014 Series A convertible preferred stock 9,022,556 15,037,593 Series B convertible preferred stock 8,416,251 — Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 362,970 77,954 Stock options 9,180,668 7,408,977 Total 31,493,724 27,035,803	Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Years Ended December 31, 2014 2013 Series A convertible preferred stock 9,022,556 15,037,594 Series B convertible preferred stock 8,416,251 — Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 362,970 109,772 Stock options 7,681,256 7,566,437 Total 29,994,312 27,225,082

Inventory (Tables)

Inventory (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following: March 31, 2015 December 31, 2014 (In thousands) Component parts (1) $ 136 $ 76 Work-in-process (2) 849 219 Finished goods 1,234 1,972 Total inventory 2,219 2,267 Inventory reserve (167 ) (533 ) Inventory — net $ 2,052 $ 1,734 (1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator. (2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.	Inventory consisted of the following: December 31, 2014 2013 (In thousands) Component parts (1) $ 76 $ 266 Work-in-process (2) 219 587 Finished goods 1,972 1,343 Total inventory 2,267 2,196 Inventory reserve (533 ) (410 ) Inventory — net $ 1,734 $ 1,786 (1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator. (2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by U.S. or EU regulatory authorities.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: December 31, 2014 2013 (In thousands) Furniture and fixtures $ 367 $ 308 Office equipment 652 425 Software 601 439 Leasehold improvements 417 82 Manufacturing equipment 974 937 Total property and equipment 3,011 2,191 Less accumulated depreciation and amortization (1,358 ) (1,209 ) Property and equipment — net $ 1,653 $ 982

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Future Amortization Expense	The estimated future amortization expense as of March 31, 2015 for the remaining periods in the next five years and thereafter is as follows (in thousands): Ending December 31 2015 $ 1,461 2016 1,940 2017 1,940 2018 1,940 2019 1,940 Thereafter 14,790 Total $ 24,011	The estimated remaining amortization as of December 31, 2014 is as follows (in thousands): Years Ending December 31 2015 $ 1,940 2016 1,940 2017 1,940 2018 1,940 2019 1,940 Thereafter 14,790 Total $ 24,490

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following: March 31, 2015 December 31, 2014 (In thousands) Accrued clinical investigator expenses $ 378 $ 309 Accrued compensation expenses 474 226 Other accrued expenses 857 419 Total accrued expenses $ 1,709 $ 954	Accrued expenses consisted of the following: December 31, 2014 2013 (In thousands) Accrued clinical investigator expenses $ 309 $ 562 Accrued other compensation expenses 226 106 Other accrued expenses 419 266 Total accrued expenses $ 954 $ 934

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Principal Payments Under Note Payable	As of December 31, 2014 a schedule of future minimum principal payments under the Note Payable is as follows (in thousands): Years Ending December 31 2015 $ 1,023 2016 12,968 2017 14,487 2018 6,522 Total $ 35,000
Schedule of Future Minimum Rental Payments for Operating Leases	At December 31, 2014 , a schedule by year of future minimum payments under operating leases is as follows (in thousands): Years Ending December 31 2015 $ 376 2016 509 2017 516 2018 525 2019 485 Thereafter 618 Total $ 3,029
Schedule by Year of Future Minimum Payments under Capital Leases, Together with Present Value of Minimum Lease Payments	At December 31, 2014 , a schedule by year of future minimum payments under capital leases, together with the present value of minimum lease payments, is as follows (in thousands): Years Ending December 31 2015 12 2016 9 Total 21 Less amount representing interest (2 ) Present value of minimum lease payments 19 Less current portion (11 ) Non-current portion $ 8
Schedule of Property and Equipment Under Capital Leases	Property and equipment under capital leases, which are included in property and equipment (Note 5), consisted of the following: December 31, 2014 2013 (In thousands) Office equipment $ 33 $ 33 Less accumulated amortization (16 ) (5 ) Total $ 17 $ 28

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Transactions	The following table presents a summary of stock option activity for the three months ended March 31, 2015 and 2014: Three Months Ended March 31, 2015 2014 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 7,681,256 $ 3.03 7,566,438 $ 2.74 Grants 1,598,500 5.49 — — Forfeitures (33,140 ) 4.64 — — Exercises (65,948 ) 1.90 (157,461 ) 1.82 Options outstanding at period end 9,180,668 3.46 7,408,977 2.76 Options exercisable at period end 4,750,021 3.18 3,584,416 3.14 Weighted average per share fair value of options granted during the period $ 4.29 $ —	A summary of stock option transactions under the plans are as follows: Years Ended December 31, 2014 2013 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 7,566,438 $ 2.74 5,493,079 $ 2.67 Grants 716,500 5.56 2,630,000 2.71 Forfeitures (210,375 ) 3.10 (513,059 ) 1.96 Exercises (391,307 ) 1.97 (43,582 ) 1.64 Options outstanding at year end 7,681,256 3.03 7,566,438 2.74 Options exercisable at year end 4,452,274 3.17 3,304,981 3.09 Weighted average per share fair value of options granted during the year $ 4.43 $ 2.14
Summary of Additional Stock Option Transactions	The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of March 31, 2015 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 9,180,668 $ 3.46 7.37 years $ 18,023 Exercisable 4,750,021 3.18 5.92 years 11,466 Outstanding, vested and expected to vest 8,549,361 3.42 7.24 years 17,241 The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of December 31, 2014 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 7,681,256 $ 3.03 7.05 years $ 21,710 Exercisable 4,452,274 3.17 5.87 years 12,887 Outstanding, vested and expected to vest 7,258,603 3.04 6.95 years 20,574	The following table provides additional information related to outstanding stock options, fully vested stock options, and stock options expected to vest as of December 31, 2014 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 7,681,256 $ 3.03 7.05 years $ 21,710 Exercisable 4,452,274 3.17 5.87 years 12,887 Outstanding, vested and expected to vest 7,258,603 3.04 6.95 years 20,574
Weighted-Average Assumptions Used for Option Grants		The Company estimated the fair value of options granted using the Black-Scholes option pricing model. Use of a valuation model requires the Company to make certain assumptions with respect to selected model inputs. Changes in these input variables would affect the amount of expense associated with equity-based compensation. Expected volatility is based on the historical volatility of the Company's common shares over the expected term of the stock option grant. To estimate the expected term, the Company utilizes the “simplified” method for “plain vanilla” options as discussed within the Securities and Exchange Commission’s Statement of Accounting Bulletin 107. The Company intends to utilize the simplified method for the foreseeable future until more detailed information about exercise behavior will be more widely available. The risk-free interest rate is based on U.S. Treasury Daily Treasury Yield Curve Rates corresponding to the expected life assumed at the date of grant. Dividend yield is zero as there are no payments of dividends made or expected. The weighted-average assumptions used for option grants were as follows: Years Ended December 31, 2014 2013 Risk-free interest rate 1.79 % 1.73 % Volatility factor 102.54 % 100.76 % Grant date fair value of common stock $ 4.43 $ 2.14 Weighted-average expected life 5.89 years 5.92 years Assumed forfeiture rate 10.00 % 10.00 %
Employee Stock-Based Compensation Expense		Employee stock-based compensation expense related to stock options recognized under ASC 718 was as follows: Years Ended December 31, 2014 2013 (In thousands) Sales and marketing $ 548 $ 366 Research, development and medical affairs 981 504 General and administrative 2,274 1,586 Total employee stock-based compensation expense $ 3,803 $ 2,456
Outstanding and Exercisable Options		The following table summarizes outstanding and exercisable options at December 31, 2014 : Options Outstanding Options Exercisable Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Number Exercisable Weighted Average Remaining Contractual Life $1.33 - $1.99 3,408,452 6.32 2,309,473 5.61 $2.00 - $2.99 2,442,796 7.70 1,020,648 5.98 $3.00 - $4.99 449,564 6.26 345,813 5.43 $5.00 - $10.99 1,019,794 8.71 415,690 7.46 $11.00 - $11.91 360,650 5.78 360,650 5.78 7,681,256 4,452,274

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Net Loss before Taxes	The components of net loss before taxes are as follows: Years Ended December 31, 2014 2013 (In thousands) United States $ (12,102 ) $ (29,303 ) Foreign (23,458 ) (16,926 ) Loss before provision for income taxes $ (35,560 ) $ (46,229 )
Components of Income Tax Benefit	The provision for income taxes consists of the following components: Years Ended December 31, 2014 2013 (In thousands) Current benefit (expense): Federal $ — $ — State — — Foreign 174 — Current income tax expense $ 174 $ — Years Ended December 31, 2014 2013 (In thousands) Deferred benefit (expense): Federal $ 3,050 $ (18,565 ) State 355 (2,162 ) Foreign (3,161 ) 3,160 244 (17,567 ) Valuation allowance (244 ) 17,567 Deferred income tax (benefit) expense $ — $ —
Net Deferred Tax Assets (Liabilities)	Worldwide net deferred tax assets and liabilities are as follows: December 31, 2014 2013 Deferred tax assets (current and non-current) (In thousands) Depreciation and amortization $ 8 $ 34 Other deferred tax assets 3,305 1,906 NOL carry-forwards 32,191 33,454 Research and development costs 5,167 6,142 Collaboration agreement receivable reserves 5,749 4,638 Valuation allowance (46,400 ) (46,156 ) Total deferred tax assets $ 20 $ 18 Deferred tax liabilities (current and non-current) Unrealized foreign currency gains $ (20 ) $ (18 ) Other deferred tax liabilities — — Total deferred tax liabilities (20 ) (18 ) Net deferred tax assets and deferred tax liabilities (current and non-current) $ — $ — In Accordance with ASC 740-10-45-4, the Company presents below the current and non-current components of the Company's deferred tax assets and deferred tax liabilities. The Company has applied the jurisdictional netting requirements of ASC 740-10-45-5 to allocate the valuation allowance between current and non-current deferred tax assets on a jurisdictional basis. The current deferred tax liability and the non-current deferred tax asset disclosed below are attributable to the United States. Deferred tax positions in each foreign jurisdiction net to zero on both a current and non-current basis. Years Ended December 31, 2014 2013 (In thousands) Current deferred tax liability $ (20 ) $ (18 ) Non-current deferred tax asset 20 18
Reconciliation of Income Tax Benefit to Amount Determined by Applying U.S. Federal Statutory Income Tax Rate	A reconciliation from the federal statutory rate to the total provision for income taxes is as follows: Years Ended December 31, 2014 2013 Amount Percent Amount Percent Federal tax benefit at statutory rate $ (12,150 ) 34.0 % $ (15,718 ) 34.0 % State tax — net of federal benefit (479 ) 1.3 (1,160 ) 2.5 Permanent items and other 331 (0.9 ) 31,851 (68.9 ) Prior period transfer pricing adjustments 3,502 (9.8 ) — — Foreign rate differential 8,190 (22.9 ) 2,594 (5.6 ) Other 536 (1.5 ) — — Change in valuation allowance 244 (0.7 ) (17,567 ) 38.0 Total tax benefit (expense) $ 174 (0.5 )% $ — — %

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: March 31, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 4,510 $ — $ — $ 4,510 Assets measured at fair value $ 4,510 $ — $ — $ 4,510 Liabilities: Derivative warrant liability (2) $ — $ 13,592 $ — $ 13,592 Liabilities measured at fair value $ — $ 13,592 $ — $ 13,592 December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 65,509 $ — $ — $ 65,509 Assets measured at fair value $ 65,509 $ — $ — $ 65,509 Liabilities: Derivative warrant liability (2) $ — $ 16,098 $ — $ 16,098 Liabilities measured at fair value $ — $ 16,098 $ — $ 16,098 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 65,509 $ — $ — $ 65,509 Assets measured at fair value $ 65,509 $ — $ — $ 65,509 Liabilities: Derivative warrant liability (2) $ — $ 16,098 $ — $ 16,098 Liabilities measured at fair value $ — $ 16,098 $ — $ 16,098 December 31, 2013 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 6,944 $ — $ — $ 6,944 Assets measured at fair value $ 6,944 $ — $ — $ 6,944 Liabilities: Derivative warrant liability (2) $ — $ 16,381 $ — $ 16,381 Liabilities measured at fair value $ — $ 16,381 $ — $ 16,381 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of segment reporting information	The following table presents a summary of the Company's reporting segments for the years ended December 31, 2014 and 2013: Year Ended December 31, 2014 Year Ended December 31, 2013 U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 17 $ 8,406 $ 8,423 $ — $ 1,872 $ 1,872 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1 ) (1,441 ) (1,442 ) — (1,863 ) (1,863 ) GROSS PROFIT 16 6,965 6,981 — 9 9 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 5,400 6,411 11,811 4,110 4,748 8,858 GENERAL AND ADMINISTRATIVE EXPENSES 7,496 4,875 12,371 5,048 4,427 9,475 SALES AND MARKETING EXPENSES 4,704 10,383 15,087 891 15,051 15,942 DEPRECIATION AND AMORTIZATION 657 2 659 138 — 138 OPERATING EXPENSES 18,257 21,671 39,928 10,187 24,226 34,413 NET LOSS FROM OPERATIONS (18,241 ) (14,706 ) (32,947 ) (10,187 ) (24,217 ) (34,404 ) OTHER INCOME AND EXPENSES, NET (2,789 ) (11,825 ) NET (LOSS) INCOME BEFORE TAXES $ (35,736 ) $ (46,229 ) The following table presents a summary of the Company's reporting segments for the three months ended March 31, 2015 and 2014: Three Months Ended March 31, 2015 Three Months Ended U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 2,443 $ 1,495 $ 3,938 $ — $ 2,084 $ 2,084 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (138 ) (145 ) (283 ) — (564 ) (564 ) GROSS PROFIT 2,305 1,350 3,655 — 1,520 1,520 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,379 1,950 3,329 1,150 1,604 2,754 GENERAL AND ADMINISTRATIVE EXPENSES 2,188 1,431 3,619 1,651 1,243 2,894 SALES AND MARKETING EXPENSES 4,880 2,249 7,129 361 2,922 3,283 DEPRECIATION AND AMORTIZATION 558 14 572 33 — 33 OPERATING EXPENSES 9,005 5,644 14,649 3,195 5,769 8,964 NET LOSS FROM OPERATIONS (6,700 ) (4,294 ) (10,994 ) (3,195 ) (4,249 ) (7,444 ) OTHER INCOME AND EXPENSES, NET 1,270 (13,315 ) NET (LOSS) INCOME BEFORE TAXES $ (9,724 ) $ (20,759 )

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail) - ILUVIEN - Patient	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Nature Of Operations [Line Items]
Post-authorization open study period	5 years	5 years
Number of patients involved in post-authorization open study period	800	800

Basis of Presentation - Reclass

Basis of Presentation - Reclassifications (Details) - Adjustment To Prior Period - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Depreciation and amortization
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Depreciation	$ 33,000		$ 138,000
Research and development expenses
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Medical affairs support expense	$ 128,000	$ 448,000	$ 429,000

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Prior Period Adjustments (Details) - Prior Period Adjustment - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Depreciation and amortization
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Depreciation	$ 33,000		$ 138,000
Research and development expenses
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Medical affairs support expense	$ 128,000	$ 448,000	$ 429,000

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Research and development expense	$ 1,300,000	$ 1,300,000	$ 7,600,000	$ 3,900,000
Cash and cash equivalents	$ 61,328,000	$ 41,326,000	$ 76,697,000	$ 12,628,000	$ 49,564,000
Percentage of cash and cash equivalents in domestic financial institutions			96.00%	100.00%
Accounts receivable write-offs			$ 21,000,000	$ 0
Useful life of intangible assets			13 years

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Long Lived Assets (Details)	12 Months Ended
	Dec. 31, 2014
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	29 months
Office Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Software
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Securities Not Included in Computation of Diluted EPS (Detail) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Securities not included in the computation of diluted EPS
Total potentially dilutive securities	31,493,724	27,035,803	29,994,312	27,225,082
Series A convertible preferred stock
Securities not included in the computation of diluted EPS
Total potentially dilutive securities	9,022,556	15,037,593	9,022,556	15,037,594
Series B convertible Preferred Stock
Securities not included in the computation of diluted EPS
Total potentially dilutive securities	8,416,251	0	8,416,251	0
Series A convertible preferred stock warrants
Securities not included in the computation of diluted EPS
Total potentially dilutive securities	4,511,279	4,511,279	4,511,279	4,511,279
Common stock warrants
Securities not included in the computation of diluted EPS
Total potentially dilutive securities	362,970	77,954	362,970	109,772
Stock options
Securities not included in the computation of diluted EPS
Total potentially dilutive securities	9,180,668	7,408,977	7,681,256	7,566,437

Factors Affecting Operations -

Factors Affecting Operations - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (323,048)	$ (313,255)	$ (277,345)
Cash and cash equivalents		$ 76,697

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Inventory net realizable value
Component parts	$ 136	[1]	$ 76	[1],[2]	$ 266	[2]
Work-in-process	849	[3]	219	[3],[4]	587	[4]
Finished goods	1,234		1,972		1,343
Inventory, Gross	2,219		2,267		2,196
Inventory reserve	(167)		(533)		(410)
Inventory — net	$ 2,052		$ 1,734		$ 1,786
[1]	Component parts inventory consisted of manufactured components of the ILUVIEN applicator.
[2]	Component parts inventory consisted of manufactured components of the ILUVIEN applicator.
[3]	Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.
[4]	Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by U.S. or EU regulatory authorities.

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Furniture and fixtures		$ 367	$ 308
Office equipment		652	425
Software		601	439
Leasehold improvements		417	82
Manufacturing equipment		974	937
Total property and equipment		3,011	2,191
Less accumulated depreciation and amortization		(1,358)	(1,209)
Property and equipment — net	$ 2,511	$ 1,653	$ 982

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 149	$ 138

Intangible Assets - Activity (D

Intangible Assets - Activity (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net		$ 24,011,000	$ 24,490,000	$ 0	$ 0
Useful life			13 years
Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net		24,011,000	$ 24,490,000
Intangible assets, gross		$ 25,000,000	$ 25,000,000
Useful life		13 years	13 years
Intangible asset amortization expense		$ 479,000	$ 510,000
pSivida
Finite-Lived Intangible Assets [Line Items]
Additional milestone payment after the first product approved by the FDA	$ 25,000,000		$ 25,000,000

Intangible Assets Intangible As

Intangible Assets Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Total	$ 24,011	$ 24,490	$ 0	$ 0
Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
2,015		1,940
2,015	1,461
2,016	1,940	1,940
2,017	1,940	1,940
2,018	1,940	1,940
2,019	1,940	1,940
Thereafter	14,790	14,790
Total	$ 24,011	$ 24,490

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of accrued expenses
Accrued clinical investigator expenses	$ 378	$ 309	$ 562
Accrued other compensation expenses	474	226	106
Other accrued expenses	857	419	266
Total accrued expenses	$ 1,709	$ 954	$ 934

License Agreements - Additional

License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of net profits			20.00%
Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN			33.00%
Recovery of commercialization costs			20.00%
Commercialization costs owned			$ 15,144,000	$ 12,219,000
pSivida
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Minimum days to require to revert license in case of breaches of contract		30 days	30 days
Maximum days to require to revert license in case of breaches of contract		90 days	90 days
Period of bankruptcy petition proceedings remains undismissed		60 days	60 days
Share of net profits		20.00%
Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN		33.00%
Recovery of commercialization costs		20.00%
Commercialization costs owned		$ 15,325,000	$ 12,956,000
Additional milestone payment after the first product approved by the FDA	$ 25,000,000		$ 25,000,000

Loan Agreements - Additional In

Loan Agreements - Additional Information (Detail)	1 Months Ended				12 Months Ended
	Sep. 30, 2014USD ($)	Apr. 30, 2014USD ($)$ / sharesshares	May. 31, 2013USD ($)Installment$ / sharesshares	Oct. 31, 2010USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)shares	Aug. 31, 2011Installment	May. 31, 2011USD ($)	Dec. 31, 2010shares
Debt Instrument [Line Items]
Increase of term loan				$ 11,000,000
Warrants issued to Lenders to purchase common stock (in shares) | shares					362,970	109,772
Exercise price on warrants (in dollars per share) | $ / shares			$ 2.86
Loss on early extinguishment of debt					$ 440,000	$ 153,000
Number of shares called by warrants | shares			31,818						39,773
Number of shares called by warrants, remaining period			7 years 4 months 24 days
Silicon Valley Bank (SVB) | Alimera Sciences, Ltd.
Debt Instrument [Line Items]
An upfront fee payment to Lenders			$ 25,000
Silicon Valley Bank (SVB) | Alimera Sciences, Inc.
Debt Instrument [Line Items]
Increase of term loan			$ 11,000,000
Exercise price on warrants (in dollars per share) | $ / shares			$ 2.86
Lenders hold warrants to purchase an aggregate of common stock | shares			54,090
Number of shares called by warrants | shares			31,818
Number of shares exercisable prior to re-pricing | shares			15,909
Number of shares called by warrants, remaining period			7 years 4 months 24 days
Estimated incremental fair value received by the holder upon re-pricing of warrants			$ 46,000
Hercules Technology Growth Capital | Alimera Sciences, Inc.
Debt Instrument [Line Items]
Increase of term loan		$ 25,000,000
Exercise price on warrants (in dollars per share) | $ / shares		$ 6.14
Number of shares called by warrants | shares		285,016
Percent of warrants exercisable upon closing		60.00%
Percent of warrants exercisable upon satisfying certain conditions		40.00%
2010 Term Loan
Debt Instrument [Line Items]
Advance term loan				6,250,000
Increase of term loan				11,000,000
Frequency of periodic payment monthly installments | Installment							33
Interest rate on term loan							11.50%
Final interest payments, as a percentage of total amount borrowed			4.00%				4.00%
An upfront fee payment to Lenders				$ 62,500
Additional debt instrument fee amount								$ 50,000
Exercise price on warrants (in dollars per share) | $ / shares				$ 11
Exercisable term of warrants				10 years
Fair value on warrants				$ 389,000
Discount amortized to interest expense				$ 366,000
Lenders hold warrants to purchase an aggregate of common stock | shares				69,999
Loss on early extinguishment of debt					$ 153,000
2010 Term Loan | Silicon Valley Bank (SVB)
Debt Instrument [Line Items]
Warrants issued to Lenders to purchase common stock (in shares) | shares				15,909
2010 Term Loan | MidCap Financial LLP
Debt Instrument [Line Items]
Warrants issued to Lenders to purchase common stock (in shares) | shares				23,864
Prepayment fee, percentage			1.00%
2010 Revolving Loan Agreement | Silicon Valley Bank (SVB)
Debt Instrument [Line Items]
Company entitled to borrow				$ 20,000,000
Payment of upfront fee				$ 100,000
2010 Revolving Loan Agreement | Silicon Valley Bank (SVB) | Alimera Sciences, Ltd.
Debt Instrument [Line Items]
Deferred financing costs capitalized			$ 49,000
2013 Term Loan | Silicon Valley Bank (SVB) | Alimera Sciences Limited (Limited)
Debt Instrument [Line Items]
Term loan amount			$ 5,000,000
2013 Term Loan | Silicon Valley Bank (SVB) | Alimera Sciences Limited (Limited) | Maximum
Debt Instrument [Line Items]
Debt Instrument, Prepayment Fee		$ 133,000
2013 Term Loan | Silicon Valley Bank (SVB) | Alimera Sciences, Ltd.
Debt Instrument [Line Items]
Frequency of periodic payment monthly installments | Installment			36
Interest rate on term loan			7.50%
Term loan amount			$ 5,000,000
Interest-only payment period			6 months
2013 Term Loan | Silicon Valley Bank (SVB) | Alimera Sciences, Ltd. | Maximum
Debt Instrument [Line Items]
Debt Instrument, Prepayment Fee		133,000
2013 Line of Credit | Silicon Valley Bank (SVB) | Alimera Sciences Limited (Limited)
Debt Instrument [Line Items]
Company entitled to borrow			$ 15,000,000
Termination fee amount		113,000
2013 Line of Credit | Silicon Valley Bank (SVB) | Alimera Sciences, Ltd.
Debt Instrument [Line Items]
Company entitled to borrow			$ 15,000,000
Eligible accounts receivable percentage used to determine advances against line of credit			80.00%
Unused capacity commitment fee percentage			0.25%
Commitment fee payment			$ 100,000
Termination fee amount		$ 113,000
2013 Line of Credit | Silicon Valley Bank (SVB) | Alimera Sciences, Ltd. | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate			2.75%
2014 Term Loan | Hercules Technology Growth Capital | Alimera Sciences, Inc.(Company)
Debt Instrument [Line Items]
Increase of term loan	$ 25,000,000
Exercise price on warrants (in dollars per share) | $ / shares		$ 6.14
Number of shares called by warrants | shares		285,016
Percent of warrants exercisable upon closing		60.00%
Percent of warrants exercisable upon satisfying certain conditions		40.00%
2014 Term Loan | Hercules Technology Growth Capital | Alimera Sciences Limited (Limited)
Debt Instrument [Line Items]
Increase of term loan	25,000,000
An upfront fee payment to Lenders		$ 262,500
Company entitled to borrow		35,000,000
Term loan amount		$ 10,000,000
Basis spread on variable rate		7.65%
Debt Issuance Cost	375,000	$ 383,000
Prepayment fee percentage within the first year of borrowing		1.25%
2014 Term Loan | Hercules Technology Growth Capital | Alimera Sciences Limited (Limited) | Minimum
Debt Instrument [Line Items]
Interest rate on term loan		10.90%
2014 Term Loan | Hercules Technology Growth Capital | Alimera Sciences, Ltd.
Debt Instrument [Line Items]
Increase of term loan	25,000,000
An upfront fee payment to Lenders		$ 262,500
Company entitled to borrow		35,000,000
Term loan amount		$ 10,000,000
Basis spread on variable rate		7.65%
Debt Issuance Cost	$ 375,000	$ 383,000
Prepayment fee percentage within the first year of borrowing		1.25%
2014 Term Loan | Hercules Technology Growth Capital | Alimera Sciences, Ltd. | Minimum
Debt Instrument [Line Items]
Interest rate on term loan		10.90%
2014 Term Loan | Hercules Technology Growth Capital | Alimera Sciences, Inc.
Debt Instrument [Line Items]
Increase of term loan		$ 25,000,000
Exercise price on warrants (in dollars per share) | $ / shares		$ 6.14
Number of shares called by warrants | shares		285,016
Fair value of warrants		$ 1,349,000
Discount		$ 1,277,000
Percent of warrants exercisable upon closing		60.00%
Percent of warrants exercisable upon satisfying certain conditions		40.00%

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Principal Payments Under Note Payable (Detail) - Note Payable $ in Thousands	Dec. 31, 2014USD ($)
Long Term Debt Maturities Repayments Of Principal [Line Items]
2,015	$ 1,023
2,016	12,968
2,017	14,487
2,018	6,522
Total	$ 35,000

Commitments and Contingencies55

Commitments and Contingencies - Schedule of Operating Lease Assets (Details) $ in Thousands	Dec. 31, 2014USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,015	$ 376
2,016	509
2,017	516
2,018	525
2,019	485
Thereafter	618
Total	$ 3,029

Commitments and Contingencies56

Commitments and Contingencies - Schedule by Year of Future Minimum Payments under Capital Leases, Together with Present Value of Minimum Lease Payments (Detail) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,015		$ 12
2,016		9
Total		21
Less amount representing interest		(2)
Present value of minimum lease payments		19
Less current portion	$ (253)	(11)	$ (10)
Non-current portion		$ 8

Commitments and Contingencies57

Commitments and Contingencies - Property and Equipment Under Capital Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Office equipment	$ 33	$ 33
Less accumulated amortization	(16)	(5)
Total	$ 17	$ 28

Commitments and Contingencies58

Commitments and Contingencies - Additional Information (Detail)	Jan. 01, 2015USD ($)Employee	Feb. 29, 2012USD ($)	Feb. 28, 2010	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)Employee	Dec. 31, 2013USD ($)	Mar. 31, 2015USD ($)
Commitments and Contingencies [Line Items]
Proceeds from issuance of notes payable					$ 35,000,000	$ 5,000,000
Accrued and unpaid interest payable on Note Payable					324,000	0
Rent expense under all operating leases					521,000	576,000
Depreciation expense					149,000	138,000
Percentage of order of ILUVIEN units required			80.00%
Agreement period			6 years
Renewal option additional period			1 year
Prior written notice period			12 months
Outsourced services payable					1,466,000	603,000	$ 827,000
Accrued milestone payments					$ 2,000,000	0	$ 0
Number of employees engaged in commercialization projects with partner company, partially dedicated | Employee					3
Number of employees engaged in commercialization projects with partner company, fully dedicated | Employee					16
Number of executives in employment agreements | Employee	5				5
Minimum
Commitments and Contingencies [Line Items]
Executives salaries	$ 309,000
Maximum
Commitments and Contingencies [Line Items]
Executives salaries	$ 504,000
CRO Agreement, physician utilization study
Commitments and Contingencies [Line Items]
Clinical and data management services					$ 16,000	690,000
Outsourced services payable					0	30,000
Consultant agreement, FDA approval
Commitments and Contingencies [Line Items]
Clinical and data management services					425,000	1,700,000
Clinical and data management services contingent upon drug approval by the FDA		$ 2,000,000
Quintiles Commercial Europe Limited
Commitments and Contingencies [Line Items]
Clinical and data management services					5,800,000
Outsourced services payable					1,443,000
Prepaid clinical and data management services					703,000
Quintiles Commercial Europe Limited | Forecast
Commitments and Contingencies [Line Items]
Clinical and data management services				$ 4,400,000
Office equipment under capital leases
Commitments and Contingencies [Line Items]
Depreciation expense					$ 11,000	$ 11,000

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - USD ($)	Dec. 12, 2014	Jun. 30, 2013	Oct. 02, 2012	Sep. 30, 2014	Apr. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Number of preferred stock and warrants.			1,000,000
Warrants to purchase additional shares			300,000
Gross proceeds under securities purchase agreement			$ 40,000,000
Estimated total stock issuance cost			$ 560,000
Gross proceeds under securities purchase agreement per value			$ 40
Initial conversion price (in dollars per share)			2.91
Initial conversion price subjected to adjustment (in dollars per share)			3.16
Initial conversion price subjected to adjustment two (in dollars per share)		$ 2.66	2.66
Voluntary conversion price not subjected to adjustments (in dollars per share)			3.16
Preferred stock converted to common stock per share (in dollars per share)			$ 10
Proceeds from issuance of preferred stock			$ 30,000,000
Contingent beneficial conversion feature		$ 4,950,000						$ 750,000	$ 4,950,000
Proportion of each unit of shares (in shares)			0.30
Exercise price of warrants (in dollars per share)			$ 44
Estimated fair value of derivatives						$ 13,592,000		16,098,000	16,381,000
Gain (loss) on change in fair value of derivatives						2,506,000	$ (13,130,000)	(283,000)
Payment of stock issuance cost						$ 0	$ 2,389,000	2,389,000	0
Intrinsic value of beneficial conversion feature								0	0
Common Stock
Class of Stock [Line Items]
Common stock issued upon conversion of convertible securities (shares)				3,759,398	2,255,639
Series A convertible preferred stock
Class of Stock [Line Items]
Number of preferred stock and warrants.			1,000,000
Warrants to purchase additional shares			300,000
Gross proceeds under securities purchase agreement			$ 40,000,000
Estimated total stock issuance cost			$ 560,000
Gross proceeds under securities purchase agreement per value			$ 40
Initial conversion price (in dollars per share)			2.66
Preferred stock converted to common stock per share (in dollars per share)			$ 10
Proceeds from issuance of preferred stock			$ 30,000,000
Proportion of each unit of shares (in shares)			0.30
Exercise price of warrants (in dollars per share)			$ 44
Shares converted (in shares)				250,000	150,000
Series B convertible Preferred Stock
Class of Stock [Line Items]
Issuance of preferred stock (in shares)	8,291.873
Issuance of preferred stock	$ 50,000,000							49,568,000	$ 0
Issuance of preferred stock (in dollars per share)	$ 6,030
Payment of stock issuance cost	$ 432,000
Common stock issued upon conversion (per preferred share)	1,000
Ownership interest of holders after conversion of preferred stock (percent)	9.98%
Intrinsic value of beneficial conversion feature								$ 750,000
Over-Allotment Option [Member] | Series B convertible Preferred Stock
Class of Stock [Line Items]
Issuance of preferred stock (in shares)	124.378

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Stock Option Transactions (Detail) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Options
Options outstanding at beginning of period (in shares)	7,681,256	7,566,438	7,566,438	5,493,079
Grants (in shares)	1,598,500	0	716,500	2,630,000
Forfeitures (in shares)	(33,140)	0	(210,375)	(513,059)
Exercises (in shares)	(65,948)	(157,461)	(391,307)	(43,582)
Options outstanding at year end (in shares)	9,180,668	7,408,977	7,681,256	7,566,438
Options exercisable at year end (in shares)	4,750,021	3,584,416	4,452,274	3,304,981
Weighted average per share fair value of options granted during the period (in dollars per share)	$ 4.29	$ 0	$ 4.43	$ 2.14
Weighted Average Exercise Price
Options outstanding at beginning of period (in dollars per share)	3.03	2.74	2.74	2.67
Grants (in dollars per share)	5.49	0	5.56	2.71
Forfeitures (in dollars per share)	4.64	0	3.10	1.96
Exercises (in dollars per share)	1.90	1.82	1.97	1.64
Options outstanding at year end (in dollars per share)	3.46	2.76	3.03	2.74
Options exercisable at year end (in dollars per share)	$ 3.18	$ 3.14	$ 3.17	$ 3.09

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Stock Option Transactions (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding, Shares	9,180,668	7,681,256	7,408,977	7,566,438	5,493,079
Options, Weighted Average Exercise Price (in dollars per share)	$ 3.46	$ 3.03	$ 2.76	$ 2.74	$ 2.67
Outstanding, Weighted Average Contractual Term (in years)	7 years 4 months 13 days	7 years 18 days
Outstanding, Aggregate Intrinsic Value	$ 18,023	$ 21,710
Exercisable, Shares	4,750,021	4,452,274	3,584,416	3,304,981
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.18	$ 3.17	$ 3.14	$ 3.09
Exercisable, Weighted Average Contractual Term (in years)	5 years 11 months 1 day	5 years 10 months 13 days
Exercisable, Aggregate Intrinsic Value	$ 11,466	$ 12,887
Expected to vest, Shares	8,549,361	7,258,603
Expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 3.42	$ 3.04
Expected to vest, Weighted Average Contractual Term (in years)	7 years 2 months 26 days	6 years 11 months 12 days
Expected to vest, Aggregate Intrinsic Value	$ 17,241	$ 20,574

Stock Incentive Plans - Weighte

Stock Incentive Plans - Weighted-Average Assumptions Used for Option Grants (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate (percent)	1.79%	1.73%
Volatility factor (percent)	102.54%	100.76%
Grant date fair value of common stock (in dollars per share)	$ 4.43	$ 2.14
Weighted-average expected life (in years)	5 years 10 months 20 days	5 years 11 months 1 day
Assumed forfeiture rate (percent)	10.00%	10.00%

Stock Incentive Plans - Employe

Stock Incentive Plans - Employee Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	$ 3,803	$ 2,456
Marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	548	366
Research, development and medical affairs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	981	504
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	$ 2,274	$ 1,586

Stock Incentive Plans - Outstan

Stock Incentive Plans - Outstanding and Exercisable Options (Detail) - Dec. 31, 2014 - $ / shares	Total
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding (shares)	7,681,256
Options Exercisable, Number Exercisable (shares)	4,452,274
$1.33 - $1.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price upper limit (in dollars per share)	$ 1.99
Exercise price lower limit (in dollars per share)	$ 1.33
Options Outstanding, Number Outstanding (shares)	3,408,452
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 3 months 25 days
Options Exercisable, Number Exercisable (shares)	2,309,473
Options Exercisable, Weighted Average Remaining Contractual Life (in years)	5 years 7 months 9 days
$2.00 - $2.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price upper limit (in dollars per share)	$ 2.99
Exercise price lower limit (in dollars per share)	$ 2
Options Outstanding, Number Outstanding (shares)	2,442,796
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 years 8 months 12 days
Options Exercisable, Number Exercisable (shares)	1,020,648
Options Exercisable, Weighted Average Remaining Contractual Life (in years)	5 years 11 months 23 days
$3.00 - $4.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price upper limit (in dollars per share)	$ 4.99
Exercise price lower limit (in dollars per share)	$ 3
Options Outstanding, Number Outstanding (shares)	449,564
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 3 months 3 days
Options Exercisable, Number Exercisable (shares)	345,813
Options Exercisable, Weighted Average Remaining Contractual Life (in years)	5 years 5 months 4 days
$5.00 - $10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price upper limit (in dollars per share)	$ 10.99
Exercise price lower limit (in dollars per share)	$ 5
Options Outstanding, Number Outstanding (shares)	1,019,794
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	8 years 8 months 15 days
Options Exercisable, Number Exercisable (shares)	415,690
Options Exercisable, Weighted Average Remaining Contractual Life (in years)	7 years 5 months 15 days
$11.00 - $11.91
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price upper limit (in dollars per share)	$ 11.91
Exercise price lower limit (in dollars per share)	$ 11
Options Outstanding, Number Outstanding (shares)	360,650
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	5 years 9 months 10 days
Options Exercisable, Number Exercisable (shares)	360,650
Options Exercisable, Weighted Average Remaining Contractual Life (in years)	5 years 9 months 10 days

Stock Incentive Plans - Addit65

Stock Incentive Plans - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2015	Jan. 02, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense					$ 3,803	$ 2,456
Contractual term (in years)			5 years 11 months 1 day		5 years 10 months 13 days
Total estimated fair value of options granted					$ 3,177	5,618
Total estimated intrinsic value of options exercised					$ 1,710	$ 79
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 1,070	$ 925
Vesting period (in years)					4 years
Contractual term (in years)			3 years 2 months 15 days		10 years
Total unrecognized compensation cost related to outstanding stock option awards			$ 10,776		$ 6,101
Total unrecognized compensation cost related to outstanding stock option awards, recognition period (in years)					2 years 8 months
Total fair value of shares vested during period					$ 3,833
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 11	$ 8
Maximum number of shares the company is authorized to grant					494,422
Additional shares that became available for future issuance	34,915	26,123
2010 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares the company is authorized to grant					774,723
Additional shares that became available for future issuance	1,772,814						2,000,000
Percentage of outstanding common stock, maximum							4.00%
Directors Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)					4 years
Contractual term (in years)					10 years

Common Stock Warrants - Additio

Common Stock Warrants - Additional Information (Detail) - USD ($)	Mar. 17, 2014	Apr. 30, 2014	May. 31, 2013	Oct. 31, 2010	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2010
Class of Warrant or Right [Line Items]
Warrants to purchase common stock issued and outstanding (in shares)					362,970	109,772
Warrants to purchase Company's common stock, granted during period (in shares)			31,818					39,773
Warrants held by lender subject to becoming exercisable on company drawing debt (in shares)			15,909				69,999
Increase of term loan				$ 11,000,000
Remaining term loan maximum availability			$ 11,000,000
Exercise price on warrants (in dollars per share)			$ 2.86
Number of shares called by warrants, remaining period			7 years 4 months 24 days
Silicon Valley Bank (SVB)
Class of Warrant or Right [Line Items]
Number of warrants exercised (in shares)	31,818
Conversion of warrants (shares issued)	18,092
Silicon Valley Bank (SVB) | Alimera Sciences, Inc.
Class of Warrant or Right [Line Items]
Warrants to purchase Company's common stock, granted during period (in shares)			31,818
Increase of term loan			$ 11,000,000
Exercise price on warrants (in dollars per share)			$ 2.86
Number of shares called by warrants, remaining period			7 years 4 months 24 days
Hercules | Alimera Sciences, Inc.
Class of Warrant or Right [Line Items]
Warrants to purchase Company's common stock, granted during period (in shares)		285,016
Increase of term loan		$ 25,000,000
Exercise price on warrants (in dollars per share)		$ 6.14
Percent of warrants exercisable upon closing		60.00%
Percent of warrants exercisable upon satisfying certain conditions		40.00%
Minimum
Class of Warrant or Right [Line Items]
Warrants to purchase common, exercise prices (in dollars per share)					$ 6.14	$ 6.14
Warrants, exercisable period from issuance date					5 years
Maximum
Class of Warrant or Right [Line Items]
Warrants to purchase common, exercise prices (in dollars per share)					$ 11	$ 11
Warrants, exercisable period from issuance date					10 years

Concentration and Credit Risk -

Concentration and Credit Risk - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)customer	Dec. 31, 2013USD ($)customer	Mar. 31, 2015USD ($)
Concentration Risk [Line Items]
Accounts receivable, net | $	$ 850	$ 500	$ 3,423
Accounts receivable | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, number of customers	0	2
Accounts receivable, net | $		$ 314
Revenue | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, number of customers	0	2
Concentration risk percentage		23.00%
Purchases | Supplier concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	42.00%
Concentration risk, number of vendors	1	2

Income Taxes - Components of Ne

Income Taxes - Components of Net Loss before Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States	$ (12,102)	$ (29,303)
Foreign	(23,458)	(16,926)
Loss before provision for income taxes	$ (35,560)	$ (46,229)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	$ 0	$ 0
State	0	0
Foreign	174	0
Current income tax expense	174	0
Deferred benefit (expense):
Federal	3,050	(18,565)
State	355	(2,162)
Foreign	(3,161)	3,160
Deferred benefit (expense), gross	244	(17,567)
Valuation allowance	(244)	17,567
Deferred benefit (expense)	$ 0	$ 0

Income Taxes - Net Deferred Tax

Income Taxes - Net Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets (current and non-current)
Depreciation and amortization	$ 8	$ 34
Other deferred tax assets	3,305	1,906
NOL carry-forwards	32,191	33,454
Research and development costs	5,167	6,142
Collaboration agreement receivable reserves	5,749	4,638
Valuation allowance	(46,400)	(46,156)
Total deferred tax assets	20	18
Deferred tax liabilities (current and non-current)
Unrealized foreign currency gains	(20)	(18)
Other deferred tax liabilities	0	0
Total deferred tax liabilities	20	18
Net deferred tax assets and deferred tax liabilities (current and non-current)	0	0
Deferred Tax Liabilities, Net, Classification [Abstract]
Current deferred tax liability	(20)	(18)
Deferred Tax Assets, Net, Classification [Abstract]
Non-current deferred tax asset	$ 20	$ 18

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Benefit to Amount Determined by Applying U.S. Federal Statutory Income Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Amount
Federal tax benefit at statutory rate	$ (12,150)	$ (15,718)
State tax — net of federal benefit	(479)	(1,160)
Permanent items and other	331	31,851
Prior period transfer pricing adjustments	3,502	0
Foreign rate differential	8,190	2,594
Other	536	0
Change in valuation allowance	244	(17,567)
Current income tax expense	$ 174	$ 0
Percent
Federal tax benefit at statutory rate	34.00%	34.00%
State tax — net of federal benefit	1.30%	2.50%
Permanent items and other	(0.90%)	(68.90%)
Prior period transfer pricing adjustments	(9.80%)	0.00%
Foreign rate differential	(22.90%)	(5.60%)
Other	(1.50%)	0.00%
Change in valuation allowance	(0.70%)	38.00%
Total tax benefit (expense)	(0.50%)	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Amount of net operating loss that could not be utilized in the future due to changes in company ownership	$ (13,700)
Cumulative book losses in foreign subsidiaries	(42,795)
Federal NOL
Income Taxes [Line Items]
Net operating loss carry-forwards	87,380	$ 82,380
State NOL
Income Taxes [Line Items]
Net operating loss carry-forwards	$ 70,840	$ 65,840

Common Stock (Detail)

Common Stock (Detail) - USD ($)	1 Months Ended			3 Months Ended		12 Months Ended
	Sep. 30, 2014	Apr. 30, 2014	Jan. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Proceeds from sale of common stock				$ 0	$ 37,500,000	$ 37,598,000	$ 53,000
Payment of stock issuance cost				$ 0	$ 2,389,000	$ 2,389,000	$ 0
Common stock
Class of Stock [Line Items]
Common stock issued upon conversion of convertible securities (shares)	3,759,398	2,255,639
Series A convertible preferred stock
Class of Stock [Line Items]
Convertible securities converted	250,000	150,000
Private placement | Common stock
Class of Stock [Line Items]
Issuance of preferred stock (in shares)			6,250,000
Share purchase price of shares issued (in dollars per share)			$ 6
Proceeds from sale of common stock			$ 37,500,000
Payment of stock issuance cost			$ 2,389,000

Fair Value - Assets Measured at

Fair Value - Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Assets:
Cash equivalents	$ 4,510	[1]	$ 65,509	[1],[2]	$ 6,944	[2]
Assets measured at fair value	4,510		65,509		6,944
Liabilities:
Derivative warrant liability	13,592	[3]	16,098	[3],[4]	16,381	[4]
Liabilities measured at fair value	13,592		16,098		16,381
Level 1
Assets:
Cash equivalents	4,510	[1]	65,509	[1],[2]	6,944	[2]
Assets measured at fair value	4,510		65,509		6,944
Liabilities:
Derivative warrant liability	0	[3]	0	[3],[4]	0	[4]
Liabilities measured at fair value	0		0		0
Level 2
Assets:
Cash equivalents	0	[1]	0	[1],[2]	0	[2]
Assets measured at fair value	0		0		0
Liabilities:
Derivative warrant liability	13,592	[3]	16,098	[3],[4]	16,381	[4]
Liabilities measured at fair value	13,592		16,098		16,381
Level 3
Assets:
Cash equivalents	0	[1]	0	[1],[2]	0	[2]
Assets measured at fair value	0		0		0
Liabilities:
Derivative warrant liability	0	[3]	0	[3],[4]	0	[4]
Liabilities measured at fair value	$ 0		$ 0		$ 0
[1]	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
[2]	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
[3]	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.
[4]	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail)	Jan. 01, 2015shares	Jan. 02, 2014shares	Apr. 30, 2010USD ($)periodshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)shares
Defined Benefit Plan Disclosure [Line Items]
Compensation expense associated with the Company's matching plan				$ 107,000	$ 95,000
Annual discretionary profit-sharing contribution				$ 0	$ 0
Employee stock purchase plan
Defined Benefit Plan Disclosure [Line Items]
Purchase price of stock under ESPP as a percentage of fair market value of common stock			85.00%	85.00%
Employee stock purchase plan, number of purchase periods | period			2
Employee stock purchase plan, purchase period			6 months
Percentage of eligible compensation that may be contributed towards ESPP			15.00%
Maximum number of shares of common stock a participant may purchase per purchase period | shares			2,500
Maximum value of shares of common stock a participant may purchase in any calendar year			$ 25,000
Common stock, available for sale under employee stock purchase plan | shares				494,422
Common shares acquired through employee stock purchase plan | shares				34,915	26,123
Additional shares that became available for future issuance under the Purchase Plan | shares	34,915	26,123
Compensation expense recorded in connection with the Purchase Plan				$ 47,000	$ 21,000

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
NET REVENUE	$ 3,938	$ 2,084	$ 8,423	$ 1,872
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(283)	(564)	(1,442)	(1,863)
GROSS PROFIT	3,655	1,520	6,981	9
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,329	2,754	11,811	8,858
GENERAL AND ADMINISTRATIVE EXPENSES	3,619	2,894	12,371	9,475
SALES AND MARKETING EXPENSES	7,129	3,283	15,087	15,942
DEPRECIATION AND AMORTIZATION	572	33	659	138
OPERATING EXPENSES	14,649	8,964	39,928	34,413
NET LOSS FROM OPERATIONS	(10,994)	(7,444)	(32,947)	(34,404)
OTHER INCOME AND EXPENSES, NET	1,270	(13,315)	(2,789)	(11,825)
NET LOSS BEFORE TAXES	(9,724)	(20,759)	(35,736)	(46,229)
Operating Segments | U.S.
Segment Reporting Information [Line Items]
NET REVENUE	2,443	0	17	0
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(138)	0	(1)	0
GROSS PROFIT	2,305	0	16	0
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,379	1,150	5,400	4,110
GENERAL AND ADMINISTRATIVE EXPENSES	2,188	1,651	7,496	5,048
SALES AND MARKETING EXPENSES	4,880	361	4,704	891
DEPRECIATION AND AMORTIZATION	558	33	657	138
OPERATING EXPENSES	9,005	3,195	18,257	10,187
NET LOSS FROM OPERATIONS	(6,700)	(3,195)	(18,241)	(10,187)
Operating Segments | International
Segment Reporting Information [Line Items]
NET REVENUE	1,495	2,084	8,406	1,872
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(145)	(564)	(1,441)	(1,863)
GROSS PROFIT	1,350	1,520	6,965	9
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,950	1,604	6,411	4,748
GENERAL AND ADMINISTRATIVE EXPENSES	1,431	1,243	4,875	4,427
SALES AND MARKETING EXPENSES	2,249	2,922	10,383	15,051
DEPRECIATION AND AMORTIZATION	14	0	2	0
OPERATING EXPENSES	5,644	5,769	21,671	24,226
NET LOSS FROM OPERATIONS	$ (4,294)	$ (4,249)	$ (14,706)	$ (24,217)